[{"authors":["admin"],"categories":null,"content":" David Michael Miller, MD, PhD, FAAD is a Board-Certified Dermatologist, Internist and Medical Oncologist at Massachusetts General Hospital and investigator in the Massachusetts General Hospital Cancer Center. The Miller Lab’s long-term goal is to identify and develop novel therapeutics for advanced skin cancer and to understand the mechanism of response and resistance to those therapies.\nDr. Miller graduated with Honors from Boston College where he earned a BA in Political Science. He received his medical (MD) and PhD degree in Biomedical Sciences from the University of Massachusetts. While at UMass, Dr. Miller received the American Diabetes Association Physician-Scientist Training Award, a Fuller Foundation grant, and he was inducted into the Alpha Omega Honor Society.\nHe then completed a Dermatology residency at Columbia University Medical Center, followed by a residency in Internal Medicine at Brigham and Women’s Hospital. Following both residencies, Dr. Miller completed fellowship training in Hematology/Oncology at Beth Israel Deaconess Medical Center and in the Oncology Center of Excellence at the Food and Drug Administration.\nDr. Miller is one of the very few clinicians in the country who is board certified in Internal Medicine, Dermatology and Medical Oncology. He currently practices both Dermatology and Medical Oncology in the Massachusetts General Hospital Cancer Center and at Massachusetts Eye and Ear Infirmary, where he co-directs multidiscliplinary clinics in advanced skin cancer, including the Merkel Cell Carcinoma Treatment Program.\nDr. Miller belongs to several professional organizations, including the American Academy of Dermatology, Medical Dermatology Society, and the American Society of Clinical Oncology. He has numerous peer-reviewed publications and he has presented his work at the Society for Investigative Dermatology, New York Academy of Medicine, the American Academy of Dermatology, and the U.S. FDA. He is also a reviewer for the British Journal of Dermatology, Journal of Investigative Dermatology, JAEDV, and Clinical Cancer Research.\nDue to his expertise in Merkel Cell Carcinoma and Squamous Cell Carcinoma, Dr. Miller has also served on advisory boards to several pharmaceutical companies, inlcuding Pfizer, Merck, Regeneron and Sanofi Genzyme.\nThe Miller Lab’s research portfolio consists of clinical and translational projects in Merkel Cell carcinoma, cutaneous Squamous Cell Carcinoma and Melanoma. Dr. Miller has received support for his research from the NIH in the form of a loan repayment award, a Research Grant from the American Skin Association, the Paul Carbone, MD fellowship award from ECOG-ACRIN, and the Mentoring Award in Oncology, Advanced Analytics and Regulatory Science from Project Data Sphere.\nBoard Certifications\nDermatology, American Board of Dermatology\nInternal Medicine, American Board of Internal Medicine\nMedical Oncology, American Board of Internal Medicine\nDr. Miller’s Link to the MGH Cancer Center\n","date":1581552000,"expirydate":-62135596800,"kind":"taxonomy","lang":"en","lastmod":1581552000,"objectID":"d33c1cd8bead9ce2a6229ddb7fdca4a5","permalink":"/authors/admin/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/authors/admin/","section":"authors","summary":"David Michael Miller, MD, PhD, FAAD is a Board-Certified Dermatologist, Internist and Medical Oncologist at Massachusetts General Hospital and investigator in the Massachusetts General Hospital Cancer Center. The Miller Lab’s long-term goal is to identify and develop novel therapeutics for advanced skin cancer and to understand the mechanism of response and resistance to those therapies.\nDr. Miller graduated with Honors from Boston College where he earned a BA in Political Science.","tags":["MGH","Dermatologist","Dermatology","Massachusetts General Hosptial","Oncologist","Medical Oncology","Merkel Cell Carcinoma","Squamous Cell Carcinoma","Melanoma","Basal Cell Carcinoma"],"title":"David Michael Miller","type":"authors"},{"authors":["Sophia-Shalhout"],"categories":null,"content":"Sophia Shalhout PhD joined the Miller Lab as the Cutaneous Oncology Research Fellow in 2019. She obtained her Ph.D. in Chemistry from Wayne State University where she studied the role of activation-induced deaminase (AID) in promoting lymphoma, and developed tools to study and quantify the type of DNA damage caused by aberrant AID activity. The exploitation of AID-induced DNA damage led to the development of small molecule chemical probes to specifically target lymphoma cells.\nShe then did a postdoctoral fellowship at Boston Children's Hospital in the Camargo lab, where she worked to develop novel small molecule modulators of the Hippo Pathway for applications in both regenerative medicine and chemotherapy.\nDr. Shalhout is currently using her skills in Biology and Data Science in the Miller Lab to identify biomarkers of response to therapies for Merkel cell carcinoma.\n","date":1581552000,"expirydate":-62135596800,"kind":"taxonomy","lang":"en","lastmod":1581552000,"objectID":"b82f32945200d65b80417ddf15378b63","permalink":"/authors/sophia-shalhout/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/authors/sophia-shalhout/","section":"authors","summary":"Sophia Shalhout PhD joined the Miller Lab as the Cutaneous Oncology Research Fellow in 2019. She obtained her Ph.D. in Chemistry from Wayne State University where she studied the role of activation-induced deaminase (AID) in promoting lymphoma, and developed tools to study and quantify the type of DNA damage caused by aberrant AID activity. The exploitation of AID-induced DNA damage led to the development of small molecule chemical probes to specifically target lymphoma cells.","tags":null,"title":"Sophia Shalhout","type":"authors"},{"authors":["Farees-Saqlain"],"categories":null,"content":"Farees Saqlain MSIV is a medical student at Harvard Medical School (HMS). Farees is participating in the Scholars in Medicine Program at HMS and conducting his research in the Miller lab. His research is focused on evaluating the natural history of Merkel Cell carcinoma.\nLinks To Recent Talks By Farees Saqlain\n  MGH Cutaneous Oncology Tumor Board  ","date":1575366300,"expirydate":-62135596800,"kind":"taxonomy","lang":"en","lastmod":1575366300,"objectID":"6e1eff9aecc2afc229c8f063976e2d90","permalink":"/authors/farees-saqlain/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/authors/farees-saqlain/","section":"authors","summary":"Farees Saqlain MSIV is a medical student at Harvard Medical School (HMS). Farees is participating in the Scholars in Medicine Program at HMS and conducting his research in the Miller lab. His research is focused on evaluating the natural history of Merkel Cell carcinoma.\nLinks To Recent Talks By Farees Saqlain\n  MGH Cutaneous Oncology Tumor Board  ","tags":null,"title":"Farees Saqlain","type":"authors"},{"authors":null,"categories":null,"content":"Flexibility This feature can be used for publishing content such as:\n Online courses Project or software documentation Tutorials  The courses folder may be renamed. For example, we can rename it to docs for software/project documentation or tutorials for creating an online course.\nDelete tutorials To remove these pages, delete the courses folder and see below to delete the associated menu link.\nUpdate site menu After renaming or deleting the courses folder, you may wish to update any [[main]] menu links to it by editing your menu configuration at config/_default/menus.toml.\nFor example, if you delete this folder, you can remove the following from your menu configuration:\n[[main]] name = \u0026quot;Courses\u0026quot; url = \u0026quot;courses/\u0026quot; weight = 50  Or, if you are creating a software documentation site, you can rename the courses folder to docs and update the associated Courses menu configuration to:\n[[main]] name = \u0026quot;Docs\u0026quot; url = \u0026quot;docs/\u0026quot; weight = 50  Update the docs menu If you use the docs layout, note that the name of the menu in the front matter should be in the form [menu.X] where X is the folder name. Hence, if you rename the courses/example/ folder, you should also rename the menu definitions in the front matter of files within courses/example/ from [menu.example] to [menu.\u0026lt;NewFolderName\u0026gt;].\n","date":1536451200,"expirydate":-62135596800,"kind":"section","lang":"en","lastmod":1536451200,"objectID":"59c3ce8e202293146a8a934d37a4070b","permalink":"/courses/example/","publishdate":"2018-09-09T00:00:00Z","relpermalink":"/courses/example/","section":"courses","summary":"Learn how to use Academic's docs layout for publishing online courses, software documentation, and tutorials.","tags":null,"title":"Overview","type":"docs"},{"authors":null,"categories":null,"content":"In this tutorial, I'll share my top 10 tips for getting started with Academic:\nTip 1 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim. Donec condimentum, sem id dapibus fringilla, tellus enim condimentum arcu, nec volutpat est felis vel metus. Vestibulum sit amet erat at nulla eleifend gravida.\nNullam vel molestie justo. Curabitur vitae efficitur leo. In hac habitasse platea dictumst. Sed pulvinar mauris dui, eget varius purus congue ac. Nulla euismod, lorem vel elementum dapibus, nunc justo porta mi, sed tempus est est vel tellus. Nam et enim eleifend, laoreet sem sit amet, elementum sem. Morbi ut leo congue, maximus velit ut, finibus arcu. In et libero cursus, rutrum risus non, molestie leo. Nullam congue quam et volutpat malesuada. Sed risus tortor, pulvinar et dictum nec, sodales non mi. Phasellus lacinia commodo laoreet. Nam mollis, erat in feugiat consectetur, purus eros egestas tellus, in auctor urna odio at nibh. Mauris imperdiet nisi ac magna convallis, at rhoncus ligula cursus.\nCras aliquam rhoncus ipsum, in hendrerit nunc mattis vitae. Duis vitae efficitur metus, ac tempus leo. Cras nec fringilla lacus. Quisque sit amet risus at ipsum pharetra commodo. Sed aliquam mauris at consequat eleifend. Praesent porta, augue sed viverra bibendum, neque ante euismod ante, in vehicula justo lorem ac eros. Suspendisse augue libero, venenatis eget tincidunt ut, malesuada at lorem. Donec vitae bibendum arcu. Aenean maximus nulla non pretium iaculis. Quisque imperdiet, nulla in pulvinar aliquet, velit quam ultrices quam, sit amet fringilla leo sem vel nunc. Mauris in lacinia lacus.\nSuspendisse a tincidunt lacus. Curabitur at urna sagittis, dictum ante sit amet, euismod magna. Sed rutrum massa id tortor commodo, vitae elementum turpis tempus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean purus turpis, venenatis a ullamcorper nec, tincidunt et massa. Integer posuere quam rutrum arcu vehicula imperdiet. Mauris ullamcorper quam vitae purus congue, quis euismod magna eleifend. Vestibulum semper vel augue eget tincidunt. Fusce eget justo sodales, dapibus odio eu, ultrices lorem. Duis condimentum lorem id eros commodo, in facilisis mauris scelerisque. Morbi sed auctor leo. Nullam volutpat a lacus quis pharetra. Nulla congue rutrum magna a ornare.\nAliquam in turpis accumsan, malesuada nibh ut, hendrerit justo. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque sed erat nec justo posuere suscipit. Donec ut efficitur arcu, in malesuada neque. Nunc dignissim nisl massa, id vulputate nunc pretium nec. Quisque eget urna in risus suscipit ultricies. Pellentesque odio odio, tincidunt in eleifend sed, posuere a diam. Nam gravida nisl convallis semper elementum. Morbi vitae felis faucibus, vulputate orci placerat, aliquet nisi. Aliquam erat volutpat. Maecenas sagittis pulvinar purus, sed porta quam laoreet at.\nTip 2 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim. Donec condimentum, sem id dapibus fringilla, tellus enim condimentum arcu, nec volutpat est felis vel metus. Vestibulum sit amet erat at nulla eleifend gravida.\nNullam vel molestie justo. Curabitur vitae efficitur leo. In hac habitasse platea dictumst. Sed pulvinar mauris dui, eget varius purus congue ac. Nulla euismod, lorem vel elementum dapibus, nunc justo porta mi, sed tempus est est vel tellus. Nam et enim eleifend, laoreet sem sit amet, elementum sem. Morbi ut leo congue, maximus velit ut, finibus arcu. In et libero cursus, rutrum risus non, molestie leo. Nullam congue quam et volutpat malesuada. Sed risus tortor, pulvinar et dictum nec, sodales non mi. Phasellus lacinia commodo laoreet. Nam mollis, erat in feugiat consectetur, purus eros egestas tellus, in auctor urna odio at nibh. Mauris imperdiet nisi ac magna convallis, at rhoncus ligula cursus.\nCras aliquam rhoncus ipsum, in hendrerit nunc mattis vitae. Duis vitae efficitur metus, ac tempus leo. Cras nec fringilla lacus. Quisque sit amet risus at ipsum pharetra commodo. Sed aliquam mauris at consequat eleifend. Praesent porta, augue sed viverra bibendum, neque ante euismod ante, in vehicula justo lorem ac eros. Suspendisse augue libero, venenatis eget tincidunt ut, malesuada at lorem. Donec vitae bibendum arcu. Aenean maximus nulla non pretium iaculis. Quisque imperdiet, nulla in pulvinar aliquet, velit quam ultrices quam, sit amet fringilla leo sem vel nunc. Mauris in lacinia lacus.\nSuspendisse a tincidunt lacus. Curabitur at urna sagittis, dictum ante sit amet, euismod magna. Sed rutrum massa id tortor commodo, vitae elementum turpis tempus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean purus turpis, venenatis a ullamcorper nec, tincidunt et massa. Integer posuere quam rutrum arcu vehicula imperdiet. Mauris ullamcorper quam vitae purus congue, quis euismod magna eleifend. Vestibulum semper vel augue eget tincidunt. Fusce eget justo sodales, dapibus odio eu, ultrices lorem. Duis condimentum lorem id eros commodo, in facilisis mauris scelerisque. Morbi sed auctor leo. Nullam volutpat a lacus quis pharetra. Nulla congue rutrum magna a ornare.\nAliquam in turpis accumsan, malesuada nibh ut, hendrerit justo. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque sed erat nec justo posuere suscipit. Donec ut efficitur arcu, in malesuada neque. Nunc dignissim nisl massa, id vulputate nunc pretium nec. Quisque eget urna in risus suscipit ultricies. Pellentesque odio odio, tincidunt in eleifend sed, posuere a diam. Nam gravida nisl convallis semper elementum. Morbi vitae felis faucibus, vulputate orci placerat, aliquet nisi. Aliquam erat volutpat. Maecenas sagittis pulvinar purus, sed porta quam laoreet at.\n","date":1557010800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1557010800,"objectID":"74533bae41439377bd30f645c4677a27","permalink":"/courses/example/example1/","publishdate":"2019-05-05T00:00:00+01:00","relpermalink":"/courses/example/example1/","section":"courses","summary":"In this tutorial, I'll share my top 10 tips for getting started with Academic:\nTip 1 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim.","tags":null,"title":"Example Page 1","type":"docs"},{"authors":null,"categories":null,"content":"Here are some more tips for getting started with Academic:\nTip 3 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim. Donec condimentum, sem id dapibus fringilla, tellus enim condimentum arcu, nec volutpat est felis vel metus. Vestibulum sit amet erat at nulla eleifend gravida.\nNullam vel molestie justo. Curabitur vitae efficitur leo. In hac habitasse platea dictumst. Sed pulvinar mauris dui, eget varius purus congue ac. Nulla euismod, lorem vel elementum dapibus, nunc justo porta mi, sed tempus est est vel tellus. Nam et enim eleifend, laoreet sem sit amet, elementum sem. Morbi ut leo congue, maximus velit ut, finibus arcu. In et libero cursus, rutrum risus non, molestie leo. Nullam congue quam et volutpat malesuada. Sed risus tortor, pulvinar et dictum nec, sodales non mi. Phasellus lacinia commodo laoreet. Nam mollis, erat in feugiat consectetur, purus eros egestas tellus, in auctor urna odio at nibh. Mauris imperdiet nisi ac magna convallis, at rhoncus ligula cursus.\nCras aliquam rhoncus ipsum, in hendrerit nunc mattis vitae. Duis vitae efficitur metus, ac tempus leo. Cras nec fringilla lacus. Quisque sit amet risus at ipsum pharetra commodo. Sed aliquam mauris at consequat eleifend. Praesent porta, augue sed viverra bibendum, neque ante euismod ante, in vehicula justo lorem ac eros. Suspendisse augue libero, venenatis eget tincidunt ut, malesuada at lorem. Donec vitae bibendum arcu. Aenean maximus nulla non pretium iaculis. Quisque imperdiet, nulla in pulvinar aliquet, velit quam ultrices quam, sit amet fringilla leo sem vel nunc. Mauris in lacinia lacus.\nSuspendisse a tincidunt lacus. Curabitur at urna sagittis, dictum ante sit amet, euismod magna. Sed rutrum massa id tortor commodo, vitae elementum turpis tempus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean purus turpis, venenatis a ullamcorper nec, tincidunt et massa. Integer posuere quam rutrum arcu vehicula imperdiet. Mauris ullamcorper quam vitae purus congue, quis euismod magna eleifend. Vestibulum semper vel augue eget tincidunt. Fusce eget justo sodales, dapibus odio eu, ultrices lorem. Duis condimentum lorem id eros commodo, in facilisis mauris scelerisque. Morbi sed auctor leo. Nullam volutpat a lacus quis pharetra. Nulla congue rutrum magna a ornare.\nAliquam in turpis accumsan, malesuada nibh ut, hendrerit justo. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque sed erat nec justo posuere suscipit. Donec ut efficitur arcu, in malesuada neque. Nunc dignissim nisl massa, id vulputate nunc pretium nec. Quisque eget urna in risus suscipit ultricies. Pellentesque odio odio, tincidunt in eleifend sed, posuere a diam. Nam gravida nisl convallis semper elementum. Morbi vitae felis faucibus, vulputate orci placerat, aliquet nisi. Aliquam erat volutpat. Maecenas sagittis pulvinar purus, sed porta quam laoreet at.\nTip 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim. Donec condimentum, sem id dapibus fringilla, tellus enim condimentum arcu, nec volutpat est felis vel metus. Vestibulum sit amet erat at nulla eleifend gravida.\nNullam vel molestie justo. Curabitur vitae efficitur leo. In hac habitasse platea dictumst. Sed pulvinar mauris dui, eget varius purus congue ac. Nulla euismod, lorem vel elementum dapibus, nunc justo porta mi, sed tempus est est vel tellus. Nam et enim eleifend, laoreet sem sit amet, elementum sem. Morbi ut leo congue, maximus velit ut, finibus arcu. In et libero cursus, rutrum risus non, molestie leo. Nullam congue quam et volutpat malesuada. Sed risus tortor, pulvinar et dictum nec, sodales non mi. Phasellus lacinia commodo laoreet. Nam mollis, erat in feugiat consectetur, purus eros egestas tellus, in auctor urna odio at nibh. Mauris imperdiet nisi ac magna convallis, at rhoncus ligula cursus.\nCras aliquam rhoncus ipsum, in hendrerit nunc mattis vitae. Duis vitae efficitur metus, ac tempus leo. Cras nec fringilla lacus. Quisque sit amet risus at ipsum pharetra commodo. Sed aliquam mauris at consequat eleifend. Praesent porta, augue sed viverra bibendum, neque ante euismod ante, in vehicula justo lorem ac eros. Suspendisse augue libero, venenatis eget tincidunt ut, malesuada at lorem. Donec vitae bibendum arcu. Aenean maximus nulla non pretium iaculis. Quisque imperdiet, nulla in pulvinar aliquet, velit quam ultrices quam, sit amet fringilla leo sem vel nunc. Mauris in lacinia lacus.\nSuspendisse a tincidunt lacus. Curabitur at urna sagittis, dictum ante sit amet, euismod magna. Sed rutrum massa id tortor commodo, vitae elementum turpis tempus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean purus turpis, venenatis a ullamcorper nec, tincidunt et massa. Integer posuere quam rutrum arcu vehicula imperdiet. Mauris ullamcorper quam vitae purus congue, quis euismod magna eleifend. Vestibulum semper vel augue eget tincidunt. Fusce eget justo sodales, dapibus odio eu, ultrices lorem. Duis condimentum lorem id eros commodo, in facilisis mauris scelerisque. Morbi sed auctor leo. Nullam volutpat a lacus quis pharetra. Nulla congue rutrum magna a ornare.\nAliquam in turpis accumsan, malesuada nibh ut, hendrerit justo. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque sed erat nec justo posuere suscipit. Donec ut efficitur arcu, in malesuada neque. Nunc dignissim nisl massa, id vulputate nunc pretium nec. Quisque eget urna in risus suscipit ultricies. Pellentesque odio odio, tincidunt in eleifend sed, posuere a diam. Nam gravida nisl convallis semper elementum. Morbi vitae felis faucibus, vulputate orci placerat, aliquet nisi. Aliquam erat volutpat. Maecenas sagittis pulvinar purus, sed porta quam laoreet at.\n","date":1557010800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1557010800,"objectID":"1c2b5a11257c768c90d5050637d77d6a","permalink":"/courses/example/example2/","publishdate":"2019-05-05T00:00:00+01:00","relpermalink":"/courses/example/example2/","section":"courses","summary":"Here are some more tips for getting started with Academic:\nTip 3 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum. Sed ac faucibus dolor, scelerisque sollicitudin nisi. Cras purus urna, suscipit quis sapien eu, pulvinar tempor diam. Quisque risus orci, mollis id ante sit amet, gravida egestas nisl. Sed ac tempus magna. Proin in dui enim. Donec condimentum, sem id dapibus fringilla, tellus enim condimentum arcu, nec volutpat est felis vel metus.","tags":null,"title":"Example Page 2","type":"docs"},{"authors":["Sophia Shalhout","Myrna R. Nahas","Reed E. Drews","David Michael Miller"],"categories":null,"content":"Abstract: Cutis laxa is a rare dermatosis that is inherited or acquired and clinically features loose, wrinkled, and redundant skin with decreased elasticity. This heterogeneous connective tissue disorder may be localized or generalized, with or without internal manifestations. Generalized cutis laxa often has a cephalocaudal progression and is attributed to inflammatory cutaneous eruptions, medications, and infections. Cutis laxa is also associated with several other conditions including rheumatoid arthritis, systemic lupus erythematosus, and plasma-cell dyscrasias. Case Presentation. We report an unusual case of a 35-year-old male with progression of generalized acquired cutis laxa and vasculitis that occurred over a period of one year. No cutaneous inflammatory eruption preceded or accompanied his decreased skin elasticity, and a biopsy of the skin showed elastolysis. His cutaneous manifestation led to systemic evaluation and an eventual diagnosis of smoldering multiple myeloma accompanied by aortitis and anemia. His myeloma and vasculitis were successfully treated with cyclophosphamide, bortezomib, and dexamethasone and high-dose prednisone, respectively, with no improvement to his cutis laxa. Conclusions. The presence of monoclonal gammopathy is strongly associated with several dermatological entities such as acquired cutis laxa. We propose a new term for the dermatological manifestations caused by paraproteinemia: monoclonal gammopathy of dermatological significance, or MGODS, and stress the evaluation of an underlying gammopathy in the setting of certain dermatologic conditions, including scleromyxedema and amyloidosis. We present a case of a newly acquired cutis laxa secondary to plasma-cell dyscrasias that exemplifies MGODS, alongside a brief literature review, and underscore the clinical relevance of monoclonal gammopathies of dermatological significance.\n","date":1581552000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1581552000,"objectID":"1e6220b37d6c2373b59b119c8e89e6ea","permalink":"/publication/mgods/","publishdate":"2020-02-13T00:00:00Z","relpermalink":"/publication/mgods/","section":"publication","summary":"We present a case of Acquired Cutis Laxa associated with Monocloncal Gammopathy of Monoclonal Significance.","tags":["MGODS","Dermatology","Medical Oncology"],"title":"Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance","type":"publication"},{"authors":["David Michael Miller","Sophia Shalhout"],"categories":[],"content":" Overview  This working document is a user guide on how to enhance communication of Clinical and Translational Research by posting slides of your presentations and talks on your website using blogdown and Hugo Academic\n Hugo Academic combined with blogdown allows for the ability to host slides of your talks so viewers can follow along with your during your presentation or have as a repository for later reference  This also allows you to retain your slides and not be put in the uncomfortable position of “giving away” your precious slides that you spent countless hours on\n In particular we will focus on a pearl on how to fairly straightforwardly transform your powerpoint or pdf talk into images so they can be hosted on your Hugo Academic Website using a nice package called pdftools    Initial Steps  We are going to assume that you’ve already built your website using blogdown and Hugo Academic\n If you have not, please see our post Communicating CT Research via Website Development with R  First create a folder for your slides for the particular talk you want to post  Within your main webstie working directory  Click through content -\u0026gt; slides In the slides folder create a new folder that is specific for the slides your intended folder In that folder you will then create an index.md markdown file which will control the content of your slides\n I would also recommend creating another folder in that folder where you can store images of slides from your powerpoint presentation or pdf presentation  I make one and call it slides but you can call it whatever you want     Creating content in the index.md markdown  The YAML in that index can look like this:  authors:\n- admin\ncategories: []\ndate: “2019-12-09T00:00:00Z”\nslides:\nhighlight_style: dracula theme: black\nsummary: Slides for ODAC Melanoma Talk 1-18-2020.\ntags:\n- Melanoma\n- Dermatology\n- Medical Oncology\ntitle: Therapeutic Updates in Melanoma - IO for Earlier Stage Disease\n Underneath the YAML, you will build the content of your slides  Each set of slides will be seprated by two three dash segments such as:  You can create any content you want in these slides such as: That will create slides that look like this:   Using your actual slides from powerpoint or pdf as slides on your website  Instead of creating your slides for your website manually using Hugo Academic or blogdown you can make images of your powerpoint files and use them as a backdrop (which is my preference)\n This can produce really nice looking slides, but it can be a bit labor intensive\n One approach is to print your slides in powerpoint to pdf format and then convert each slide to a single pdf or jpg file and put those files in you slides folder that you created\n But doing this slide by slide is quite tedious  Enter a slick Data Science Solution  Make use of a wonderful package called pdftools  this allows you to convert one to all of your pdf slides to a variety of image types    pdftoolswill greatly reduce your work load   Let’s use an example from one of our presentations  In January, we had a powerpoint presentation on IO therapy in earlier stage melanoma\n After creating the powerpoint presentation we printed the ppt to pdf  That pdf was titled melanoma_odac.pdf  To faciliate the creation of the slide presentation using blogdown we made use of the pdftools package as follows:    Load the pdftools package\nlibrary(pdftools) Convert PDF to JPEG\n- Use the following code for this:\npdf_convert(\u0026quot;melanoma_odac.pdf\u0026quot;, format = \u0026quot;jpeg\u0026quot;, pages = NULL, filenames = NULL, dpi = 300, opw = \u0026quot;\u0026quot;, upw = \u0026quot;\u0026quot;, verbose = TRUE)\n Of note, melanoma_odac.pdf is the name of the pdf that you want to convert slide by slide to jpeg, this file should be in the same working directory as the Rproject that you are working with  Once you execute this function, each slide will be converted into the image format of your choosing -\u0026gt; in this case we chose jpeg  This is important, b/c it should match the code in your index.md markdown for your slides presentation\n Each slide will be automatically labeled as melanoma_odac_1.jpeg followed by melanoma_odac_2.jpeg, etc.    Important nuances of the code  pages = NULL will convert all of the slides to individual slide\n dpi = 300 is the resolution of the images that you are saving    Format your index.md appropriately  Then, if you want your jpeg slides to take up the whole entire slide, make them a backdrop\n Here is an example of what Dr. Miller’s index.md file looked like  To see how this turns out click here\n  That’s it for now, please let us know if this was helpful or if you have any additional feedback    ","date":1581379200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1581379200,"objectID":"57af5e1ef424a657fa79cf22565d790a","permalink":"/post/showcasing_presentations_on_your_website/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/post/showcasing_presentations_on_your_website/","section":"post","summary":"This working document is a user guide on how to post presentations on your a website using the packages `blogdown`, `Hugo Academic` and `pdftools`","tags":["Data Science","pdftools","Rstudio","Hugo Academic","blogdown"],"title":"Showcasing Clinical and Translational Research Presentations with Hugo Academic","type":"post"},{"authors":["Sophia Shalhout","David Michael Miller"],"categories":null,"content":"       Overview  This is an RMarkdown explaining how we can use “Swimmer Plots” to visualize survival data. A “Swimmer Plot” is a graphical way of displaying several aspects of a subject’s tumor response such as total time to tumor response, whether there was a “Complete” or “Partial” response, and duration of response. This is a clear, graphical representation of the course of a patient’s tumor response and can be an especially useful tool when reporting clinical trial data results.   Prepare the Data Step 1, Download ggplot2, reshape2, dplyr, plotly, and grid from CRAN  Use the install.package() function to install the followng R packages from CRAN: ggplot2, plotly, reshape2, dplyr, kintr and grid from CRAN for example:\ninstall.packages(\u0026quot;ggplot2\u0026quot;)   Step 2, Load each relevant Package library(ggplot2) library(dplyr, warn.conflicts=FALSE) # Useful for manipulating the dataframes library(reshape2) # Reformmating dataframes library(grid) library(plotly) # Allows us to make the swimmer plot interactive library(knitr)  Step 3, Create an “example” data set for demonstrative purposes  We will create a working data set appropriate for this type of graphical represenataion.  set.seed(35) # This sets the seed of R\u0026#39;s random number generator dat \u0026lt;- data.frame(Subject = 1:15, Months = sample(5:20, 15, replace=TRUE), # This generates a random set of months from 5 - 20 Treated=sample(0:1, 15, replace=TRUE), # This generates 15 random 0 or 1s which correspond to Tx or no Tx Stage = sample(1:4, 15, replace=TRUE), # This randomly generates staging from 1 - 4 Continued=sample(0:15, 15, replace=TRUE)) View initial Data Set dat %\u0026gt;% kable   Subject Months Treated Stage Continued    1 14 0 4 5  2 10 0 2 9  3 12 0 1 0  4 5 0 1 14  5 11 0 2 10  6 15 1 4 1  7 13 0 1 13  8 18 1 1 9  9 9 0 2 0  10 6 0 4 6  11 6 0 3 2  12 20 0 1 15  13 13 0 2 2  14 14 1 1 12  15 13 0 1 0      Add Response Data to Data Set dat \u0026lt;- dat %\u0026gt;% group_by(Subject) %\u0026gt;% mutate(Complete=sample(c(4:(max(Months)-1),NA), 1, prob=c(rep(1, length(4:(max(Months)-1))),5), replace=TRUE), Partial=sample(c(4:(max(Months)-1),NA), 1, prob=c(rep(1, length(4:(max(Months)-1))),5), replace=TRUE), Durable=sample(c(-0.5,NA), 1, replace=TRUE)) # of note, `sample()`takes a sample of the specified size from the elements of x using either with or without replacement # Let\u0026#39;s organize the order of the Subjects by Months dat$Subject \u0026lt;- factor(dat$Subject, levels=dat$Subject[order(dat$Months)]) Let’s view the Data Set Now dat %\u0026gt;% kable   Subject Months Treated Stage Continued Complete Partial Durable    1 14 0 4 5 5 11 NA  2 10 0 2 9 NA 4 -0.5  3 12 0 1 0 5 8 -0.5  4 5 0 1 14 NA NA NA  5 11 0 2 10 5 NA -0.5  6 15 1 4 1 6 6 -0.5  7 13 0 1 13 11 10 -0.5  8 18 1 1 9 15 10 NA  9 9 0 2 0 NA 6 -0.5  10 6 0 4 6 NA NA -0.5  11 6 0 3 2 4 NA -0.5  12 20 0 1 15 11 NA NA  13 13 0 2 2 8 9 -0.5  14 14 1 1 12 13 13 NA  15 13 0 1 0 NA NA -0.5      Melt part of data frame for adding points to bars  This will collapse the Columns “Complete”, “Partial” and “Durable” into a new column called “variable” and the values of those orginial columns will become a new vector/column called “value”  dat.m \u0026lt;- melt(dat %\u0026gt;% select(Subject, Months, Complete, Partial, Durable), id.var=c(\u0026quot;Subject\u0026quot;,\u0026quot;Months\u0026quot;), na.rm = TRUE) # of note, na.rm = TRUE will eliminate those rows with missing values Let’s View our Data Set after melting dat.m %\u0026gt;% kable    Subject Months variable value    1 1 14 Complete 5.0  3 3 12 Complete 5.0  5 5 11 Complete 5.0  6 6 15 Complete 6.0  7 7 13 Complete 11.0  8 8 18 Complete 15.0  11 11 6 Complete 4.0  12 12 20 Complete 11.0  13 13 13 Complete 8.0  14 14 14 Complete 13.0  16 1 14 Partial 11.0  17 2 10 Partial 4.0  18 3 12 Partial 8.0  21 6 15 Partial 6.0  22 7 13 Partial 10.0  23 8 18 Partial 10.0  24 9 9 Partial 6.0  28 13 13 Partial 9.0  29 14 14 Partial 13.0  32 2 10 Durable -0.5  33 3 12 Durable -0.5  35 5 11 Durable -0.5  36 6 15 Durable -0.5  37 7 13 Durable -0.5  39 9 9 Durable -0.5  40 10 6 Durable -0.5  41 11 6 Durable -0.5  43 13 13 Durable -0.5  45 15 13 Durable -0.5       Graph the Data using a Swimmer Plot Let’s make a static swimmer plot with ggplot a\u0026lt;- ggplot(dat, aes(Subject, Months)) + geom_bar(stat=\u0026quot;identity\u0026quot;, aes(fill=factor(Stage)), width=0.8) + geom_point(data=dat.m, aes(Subject, value, colour=variable, shape=variable), size=5) + geom_segment(data=dat %\u0026gt;% filter(Continued==1), aes(x=Subject, xend=Subject, y=Months + 0.1, yend=Months + 1), pch=15, size=0.8, arrow=arrow(type=\u0026quot;closed\u0026quot;, length=unit(0.1,\u0026quot;in\u0026quot;))) + coord_flip() + scale_fill_manual(values=hcl(seq(15,375,length.out=5)[1:4],100,75)) + scale_colour_manual(values=c(hcl(seq(15,375,length.out=3)[1:2],100,30),\u0026quot;black\u0026quot;)) + scale_y_continuous(limits=c(-1,20), breaks=0:20) + labs(fill=\u0026quot;Disease Stage\u0026quot;, colour=\u0026quot;\u0026quot;, shape=\u0026quot;\u0026quot;, x=\u0026quot;Subjects on Treatment Drug A\u0026quot;) + theme_bw() + theme(panel.grid.minor=element_blank(), panel.grid.major=element_blank(), axis.text.y=element_blank(), axis.ticks.y=element_blank()) a  Now let’s make an Interactive Swimmer plot in Plotly by simply using the ggplotly() function of the static plot as an object ggplotly(a)  {\"x\":{\"data\":[{\"orientation\":\"h\",\"width\":[0.8,0.800000000000001,0.800000000000001,0.800000000000001,0.800000000000001,0.800000000000001,0.800000000000001],\"base\":[0,0,0,0,0,0,0],\"x\":[5,12,13,13,14,18,20],\"y\":[1,7,8,10,12,14,15],\"text\":[\"factor(Stage): 1\nSubject: 4\nMonths: 5\",\"factor(Stage): 1\nSubject: 3\nMonths: 12\",\"factor(Stage): 1\nSubject: 7\nMonths: 13\",\"factor(Stage): 1\nSubject: 15\nMonths: 13\",\"factor(Stage): 1\nSubject: 14\nMonths: 14\",\"factor(Stage): 1\nSubject: 8\nMonths: 18\",\"factor(Stage): 1\nSubject: 12\nMonths: 20\"],\"type\":\"bar\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(255,146,137,1)\",\"line\":{\"width\":1.88976377952756,\"color\":\"transparent\"}},\"name\":\"(1,NA)\",\"legendgroup\":\"(1,NA)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"orientation\":\"h\",\"width\":[0.8,0.800000000000001,0.800000000000001,0.800000000000001],\"base\":[0,0,0,0],\"x\":[9,10,11,13],\"y\":[4,5,6,9],\"text\":[\"factor(Stage): 2\nSubject: 9\nMonths: 9\",\"factor(Stage): 2\nSubject: 2\nMonths: 10\",\"factor(Stage): 2\nSubject: 5\nMonths: 11\",\"factor(Stage): 2\nSubject: 13\nMonths: 13\"],\"type\":\"bar\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(150,202,0,1)\",\"line\":{\"width\":1.88976377952756,\"color\":\"transparent\"}},\"name\":\"(2,1,NA)\",\"legendgroup\":\"(2,1,NA)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"orientation\":\"h\",\"width\":0.8,\"base\":0,\"x\":[6],\"y\":[3],\"text\":\"factor(Stage): 3\nSubject: 11\nMonths: 6\",\"type\":\"bar\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(0,218,224,1)\",\"line\":{\"width\":1.88976377952756,\"color\":\"transparent\"}},\"name\":\"(3,1,NA)\",\"legendgroup\":\"(3,1,NA)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"orientation\":\"h\",\"width\":[0.8,0.800000000000001,0.800000000000001],\"base\":[0,0,0],\"x\":[6,14,15],\"y\":[2,11,13],\"text\":[\"factor(Stage): 4\nSubject: 10\nMonths: 6\",\"factor(Stage): 4\nSubject: 1\nMonths: 14\",\"factor(Stage): 4\nSubject: 6\nMonths: 15\"],\"type\":\"bar\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(225,153,255,1)\",\"line\":{\"width\":1.88976377952756,\"color\":\"transparent\"}},\"name\":\"(4,1,NA)\",\"legendgroup\":\"(4,1,NA)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"x\":[5,5,5,6,11,15,4,11,8,13],\"y\":[11,7,6,13,8,14,3,15,9,12],\"text\":[\"Subject: 1\nvalue: 5.0\nvariable: Complete\nvariable: Complete\nSubject: 1\nMonths: 5.0\",\"Subject: 3\nvalue: 5.0\nvariable: Complete\nvariable: Complete\nSubject: 3\nMonths: 5.0\",\"Subject: 5\nvalue: 5.0\nvariable: Complete\nvariable: Complete\nSubject: 5\nMonths: 5.0\",\"Subject: 6\nvalue: 6.0\nvariable: Complete\nvariable: Complete\nSubject: 6\nMonths: 6.0\",\"Subject: 7\nvalue: 11.0\nvariable: Complete\nvariable: Complete\nSubject: 7\nMonths: 11.0\",\"Subject: 8\nvalue: 15.0\nvariable: Complete\nvariable: Complete\nSubject: 8\nMonths: 15.0\",\"Subject: 11\nvalue: 4.0\nvariable: Complete\nvariable: Complete\nSubject: 11\nMonths: 4.0\",\"Subject: 12\nvalue: 11.0\nvariable: Complete\nvariable: Complete\nSubject: 12\nMonths: 11.0\",\"Subject: 13\nvalue: 8.0\nvariable: Complete\nvariable: Complete\nSubject: 13\nMonths: 8.0\",\"Subject: 14\nvalue: 13.0\nvariable: Complete\nvariable: Complete\nSubject: 14\nMonths: 13.0\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(145,12,0,1)\",\"opacity\":1,\"size\":18.8976377952756,\"symbol\":\"circle\",\"line\":{\"width\":1.88976377952756,\"color\":\"rgba(145,12,0,1)\"}},\"hoveron\":\"points\",\"name\":\"(Complete,1)\",\"legendgroup\":\"(Complete,1)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"x\":[11,4,8,6,10,10,6,9,13],\"y\":[11,5,7,13,8,14,4,9,12],\"text\":[\"Subject: 1\nvalue: 11.0\nvariable: Partial\nvariable: Partial\nSubject: 1\nMonths: 11.0\",\"Subject: 2\nvalue: 4.0\nvariable: Partial\nvariable: Partial\nSubject: 2\nMonths: 4.0\",\"Subject: 3\nvalue: 8.0\nvariable: Partial\nvariable: Partial\nSubject: 3\nMonths: 8.0\",\"Subject: 6\nvalue: 6.0\nvariable: Partial\nvariable: Partial\nSubject: 6\nMonths: 6.0\",\"Subject: 7\nvalue: 10.0\nvariable: Partial\nvariable: Partial\nSubject: 7\nMonths: 10.0\",\"Subject: 8\nvalue: 10.0\nvariable: Partial\nvariable: Partial\nSubject: 8\nMonths: 10.0\",\"Subject: 9\nvalue: 6.0\nvariable: Partial\nvariable: Partial\nSubject: 9\nMonths: 6.0\",\"Subject: 13\nvalue: 9.0\nvariable: Partial\nvariable: Partial\nSubject: 13\nMonths: 9.0\",\"Subject: 14\nvalue: 13.0\nvariable: Partial\nvariable: Partial\nSubject: 14\nMonths: 13.0\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(0,105,110,1)\",\"opacity\":1,\"size\":18.8976377952756,\"symbol\":\"triangle-up\",\"line\":{\"width\":1.88976377952756,\"color\":\"rgba(0,105,110,1)\"}},\"hoveron\":\"points\",\"name\":\"(Partial,1)\",\"legendgroup\":\"(Partial,1)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"x\":[-0.5,-0.5,-0.5,-0.5,-0.5,-0.5,-0.5,-0.5,-0.5,-0.5],\"y\":[5,7,6,13,8,4,2,3,9,10],\"text\":[\"Subject: 2\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 2\nMonths: -0.5\",\"Subject: 3\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 3\nMonths: -0.5\",\"Subject: 5\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 5\nMonths: -0.5\",\"Subject: 6\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 6\nMonths: -0.5\",\"Subject: 7\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 7\nMonths: -0.5\",\"Subject: 9\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 9\nMonths: -0.5\",\"Subject: 10\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 10\nMonths: -0.5\",\"Subject: 11\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 11\nMonths: -0.5\",\"Subject: 13\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 13\nMonths: -0.5\",\"Subject: 15\nvalue: -0.5\nvariable: Durable\nvariable: Durable\nSubject: 15\nMonths: -0.5\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(0,0,0,1)\",\"opacity\":1,\"size\":18.8976377952756,\"symbol\":\"square\",\"line\":{\"width\":1.88976377952756,\"color\":\"rgba(0,0,0,1)\"}},\"hoveron\":\"points\",\"name\":\"(Durable,1)\",\"legendgroup\":\"(Durable,1)\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"x\":[15.1,16],\"y\":[13,13],\"text\":\"Subject: 6\nMonths + 0.1: 15.1\nSubject: 13\nMonths + 1: 16\nSubject: 6\nMonths: 15.1\",\"type\":\"scatter\",\"mode\":\"lines\",\"line\":{\"width\":3.02362204724409,\"color\":\"rgba(0,0,0,1)\",\"dash\":\"solid\"},\"hoveron\":\"points\",\"showlegend\":false,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null}],\"layout\":{\"margin\":{\"t\":26.2283105022831,\"r\":7.30593607305936,\"b\":40.1826484018265,\"l\":25.5707762557078},\"plot_bgcolor\":\"rgba(255,255,255,1)\",\"paper_bgcolor\":\"rgba(255,255,255,1)\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"type\":\"linear\",\"autorange\":false,\"range\":[-2.05,21.05],\"tickmode\":\"array\",\"ticktext\":[\"0\",\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\",\"11\",\"12\",\"13\",\"14\",\"15\",\"16\",\"17\",\"18\",\"19\",\"20\"],\"tickvals\":[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20],\"categoryorder\":\"array\",\"categoryarray\":[\"0\",\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\",\"11\",\"12\",\"13\",\"14\",\"15\",\"16\",\"17\",\"18\",\"19\",\"20\"],\"nticks\":null,\"ticks\":\"outside\",\"tickcolor\":\"rgba(51,51,51,1)\",\"ticklen\":3.65296803652968,\"tickwidth\":0.66417600664176,\"showticklabels\":true,\"tickfont\":{\"color\":\"rgba(77,77,77,1)\",\"family\":\"\",\"size\":11.689497716895},\"tickangle\":-0,\"showline\":false,\"linecolor\":null,\"linewidth\":0,\"showgrid\":false,\"gridcolor\":null,\"gridwidth\":0,\"zeroline\":false,\"anchor\":\"y\",\"title\":{\"text\":\"Months\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187}},\"hoverformat\":\".2f\"},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"type\":\"linear\",\"autorange\":false,\"range\":[0.4,15.6],\"tickmode\":\"array\",\"ticktext\":[\"4\",\"10\",\"11\",\"9\",\"2\",\"5\",\"3\",\"7\",\"13\",\"15\",\"1\",\"14\",\"6\",\"8\",\"12\"],\"tickvals\":[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15],\"categoryorder\":\"array\",\"categoryarray\":[\"4\",\"10\",\"11\",\"9\",\"2\",\"5\",\"3\",\"7\",\"13\",\"15\",\"1\",\"14\",\"6\",\"8\",\"12\"],\"nticks\":null,\"ticks\":\"\",\"tickcolor\":null,\"ticklen\":3.65296803652968,\"tickwidth\":0,\"showticklabels\":false,\"tickfont\":{\"color\":null,\"family\":null,\"size\":0},\"tickangle\":-0,\"showline\":false,\"linecolor\":null,\"linewidth\":0,\"showgrid\":false,\"gridcolor\":null,\"gridwidth\":0,\"zeroline\":false,\"anchor\":\"x\",\"title\":{\"text\":\"Subjects on Treatment Drug A\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187}},\"hoverformat\":\".2f\"},\"shapes\":[{\"type\":\"rect\",\"fillcolor\":\"transparent\",\"line\":{\"color\":\"rgba(51,51,51,1)\",\"width\":0.66417600664176,\"linetype\":\"solid\"},\"yref\":\"paper\",\"xref\":\"paper\",\"x0\":0,\"x1\":1,\"y0\":0,\"y1\":1}],\"showlegend\":true,\"legend\":{\"bgcolor\":\"rgba(255,255,255,1)\",\"bordercolor\":\"transparent\",\"borderwidth\":1.88976377952756,\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":11.689497716895},\"y\":0.826771653543307},\"annotations\":[{\"text\":\"Disease Stage\n\",\"x\":1.02,\"y\":1,\"showarrow\":false,\"ax\":0,\"ay\":0,\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187},\"xref\":\"paper\",\"yref\":\"paper\",\"textangle\":-0,\"xanchor\":\"left\",\"yanchor\":\"bottom\",\"legendTitle\":true}],\"hovermode\":\"closest\",\"barmode\":\"relative\"},\"config\":{\"doubleClick\":\"reset\",\"showSendToCloud\":false},\"source\":\"A\",\"attrs\":{\"76c34d1fe2e1\":{\"fill\":{},\"x\":{},\"y\":{},\"type\":\"bar\"},\"76c368684955\":{\"x\":{},\"y\":{},\"colour\":{},\"shape\":{},\"x.1\":{},\"y.1\":{}},\"76c316a6a100\":{\"x\":{},\"y\":{},\"xend\":{},\"yend\":{},\"x.1\":{},\"y.1\":{}}},\"cur_data\":\"76c34d1fe2e1\",\"visdat\":{\"76c34d1fe2e1\":[\"function (y) \",\"x\"],\"76c368684955\":[\"function (y) \",\"x\"],\"76c316a6a100\":[\"function (y) \",\"x\"]},\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}   SessionInfo sessionInfo() ## R version 3.6.1 (2019-07-05) ## Platform: x86_64-apple-darwin15.6.0 (64-bit) ## Running under: macOS Mojave 10.14.6 ## ## Matrix products: default ## BLAS: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRblas.0.dylib ## LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRlapack.dylib ## ## locale: ## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8 ## ## attached base packages: ## [1] grid stats graphics grDevices utils datasets methods ## [8] base ## ## other attached packages: ## [1] knitr_1.26 plotly_4.9.0 reshape2_1.4.3 dplyr_0.8.3 ggplot2_3.2.1 ## ## loaded via a namespace (and not attached): ## [1] Rcpp_1.0.3 later_1.0.0 highr_0.8 pillar_1.4.3 ## [5] compiler_3.6.1 plyr_1.8.5 tools_3.6.1 digest_0.6.23 ## [9] viridisLite_0.3.0 jsonlite_1.6 evaluate_0.14 lifecycle_0.1.0 ## [13] tibble_2.1.3 gtable_0.3.0 pkgconfig_2.0.3 rlang_0.4.4 ## [17] shiny_1.4.0 crosstalk_1.0.0 yaml_2.2.0 blogdown_0.17.1 ## [21] xfun_0.11 fastmap_1.0.1 httr_1.4.1 withr_2.1.2 ## [25] stringr_1.4.0 vctrs_0.2.2 htmlwidgets_1.5.1 tidyselect_0.2.5 ## [29] glue_1.3.1 data.table_1.12.6 R6_2.4.1 rmarkdown_1.17 ## [33] bookdown_0.16 farver_2.0.3 tidyr_1.0.0 purrr_0.3.3 ## [37] magrittr_1.5 promises_1.1.0 scales_1.1.0 htmltools_0.4.0 ## [41] assertthat_0.2.1 xtable_1.8-4 mime_0.7 colorspace_1.4-1 ## [45] httpuv_1.5.2 stringi_1.4.5 lazyeval_0.2.2 munsell_0.5.0 ## [49] crayon_1.3.4  ","date":1581206400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1581206400,"objectID":"a2c5de9656c0c606394477427da7e56c","permalink":"/post/swimmer_plots/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/post/swimmer_plots/","section":"post","summary":"This working document is a user guide on how to create Swimmer Plots to visualize survival data","tags":["Swimmer Plots","Data Science"],"title":"Graphical Representation of Survival - Swimmer Plots for Clinical Trials in Clinical Oncology","type":"post"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1581162900,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1581162900,"objectID":"6bd3cac384e67763cd88b64a4d7e1f3f","permalink":"/talk/neds_updates_in_mcc-02_08_20/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/neds_updates_in_mcc-02_08_20/","section":"talk","summary":"","tags":["Dermatology","Merkel Cell Carcinoma"],"title":"Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1580474700,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1580474700,"objectID":"4bcd70101d9dcac8b9411dca87062bd4","permalink":"/talk/pds_rare_tumor_registry_workshop-01-31-20/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/pds_rare_tumor_registry_workshop-01-31-20/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","MCC Registry"],"title":"The MCC Patient Registry - From Promise to Prototype to Patient","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1580288400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1580288400,"objectID":"1ce4895f221016a4efd7c2049d50df86","permalink":"/talk/pds_mcc_registry_workshop-01-29-20/","publishdate":"2020-01-29T18:00:00Z","relpermalink":"/talk/pds_mcc_registry_workshop-01-29-20/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","MCC Registry"],"title":"MCC Patient Registry - Updates and Future Directions","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1580140800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1580140800,"objectID":"02da2e04f4904ff1ecca49d55931413b","permalink":"/talk/mgh_app_education_program_skin_toxicities_of_antineoplastic_meds-01_27_20/","publishdate":"2020-01-01T04:00:00Z","relpermalink":"/talk/mgh_app_education_program_skin_toxicities_of_antineoplastic_meds-01_27_20/","section":"talk","summary":"","tags":["Dermatology"],"title":"Skin Toxicities of Anti-Neoplastic Medications","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1579791600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1579791600,"objectID":"107372b3a185f97075cda028e4a36427","permalink":"/talk/gw_derm_resident_lecture_melanoma-01-24-20/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/gw_derm_resident_lecture_melanoma-01-24-20/","section":"talk","summary":"","tags":["Melanoma","Education","Dermatology","Medical Oncology"],"title":"Melanoma - Pathogenesis, Clinical Features, Work Up \u0026 Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1579347000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1579347000,"objectID":"d0304cc2dd711ea17e5c62667c013371","permalink":"/talk/odac_melanoma-1-18-20/","publishdate":"2019-11-12T16:00:00Z","relpermalink":"/talk/odac_melanoma-1-18-20/","section":"talk","summary":"","tags":["Melanoma","Medical Oncology","Dermatology"],"title":"Therapeutic Updates in Melanoma - IO for Earlier Stage Disease","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1579275300,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1579275300,"objectID":"ef0596c1d4a8be34d2a2dcd0f64a971d","permalink":"/talk/odac_mcc-1-17-20/","publishdate":"2019-11-12T16:00:00Z","relpermalink":"/talk/odac_mcc-1-17-20/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","Medical Oncology","Dermatology"],"title":"Merkel Cell Carcinoma- Current Concepts in Diagnosis and Management","type":"talk"},{"authors":["Sophia Shalhout","David Michael Miller"],"categories":[],"content":" Overview  Almost everyone in Academia these days has a website. Indeed, websites are a fabulous way to post content and more effectively communicate your Clinical and Translational Research.\n There are many tools and services that can assist you in developing a very functional website.\n This working document is a rough user guide on how to create a website using R via a package called blogdown. It will also walk you through opening in account on Netlify, which will host your website. There are numerous resources for webpage development, including an amazing bookdown called “blogdown: Creating Websites with R Markdown” (https://bookdown.org/yihui/blogdown/). We’ve created this resource as we have tried to provide details and pearls that we struggled with and we belive these may be helpful to others. This is a ongoing, ‘living’ document that is constantly being edited and expanded. Please provide comments to allow us to optimize this document for all R users.   Getting Started Load Packages for RMarkdown tinytex::install_tinytex()  Github Register a GitHub account (https://github.com) Create a new Repository (“+” sign in the upper right hand corner)\n Create a name for the repo and remember this as it will be used\n Copy the github repo address   R Starting Your Project Create a new project in R using version control\n   File -\u0026gt; New Project -\u0026gt; Version Control -\u0026gt; Git (clone a project from a Git repository)\n Enter the Git Repository URL:e.g. https://www.github.com/DM-Miller/themillerlab\n Create Project (open in new session would be my recommendation\n  Install blogdown  if (!requireNamespace(\u0026quot;devtools\u0026quot;)) install.packages(\u0026quot;devtools\u0026quot;) devtools::install_github(\u0026quot;rstudio/blogdown\u0026quot;) Load blogdown  library(blogdown) Create a new_site  new_site()  this will install Hugo and download new files\n The default theme is lithium If you want a different one (e.g. hugo-academic) add the following into the function:  new_site(theme = \u0026quot;gcushen/hugo-academic\u0026quot;)  Once you do this it will download all of the necessary files into your working directory  for example:      Build Your Site build_site() Use the function build_site() in the blogdown package\nblogdown::build_site()  serve_site() blogdown::serve_site() This function allows you to serve your website locally so you can view it in the “Viewer” tab in the “Files Plots Packages Help Viewer” pane ## Commit Changes to GitHub 1. Once you’ve set up your version control to github, each change that you make will be tracked by R. These changes will be cataloged in the Git Pane.\nTo commit them to GitHub, select all of the files and click on one of the check boxes.  Then click on the “Commit” button in teh above pane\n That will bring up a new window which will allow you to review the changes you’ve made. Write a message in the “Commit Message” Box in order to annotate the changes.  * Of note, these changes will show up in GitHub under “Commit”.\nThen press “Commit”. After you do that a new window will pop up called “Git Commit”.  Then press “Close”. Press “Push” in the Review Changes Pane, which will push the changes to GitHub. This window will pop up. Once it has been pushed, press “Close”. That should be it.    Netlify Overview  Netlify is a is a San Francisco-based cloud computing company that offers hosting and serverless backend services for static websites (source: https://en.wikipedia.org/wiki/Netlify).\n There are other options. We’ve used it to host our website.\n Here are a few steps to get started:  Go to netlify (https://www.netlify.com) and sign up\n We would recommend signing up with your GitHub account, especially if your are doing to deploy your website from this account\n Launch a New Site from Git\n Select Continuous Deployment from GitHub\n Pick your GitHub Repository for which you want Continuous Deployment\n Modify Settings (here’s an example)  7. Select Deploy Site 8. Select a Domain Name (you can purchase one from Netlify if it is available)\n  Designing a Website Using Hugo-Academic Overview  Hugo-Academic is a very reasonable theme for a academic website  for an example see: https://www.themillerlab.io    Configurating the Website Overview  There are several config files that you need to know about  config.toml  This file is where you will create the Title of your website\n# Title of your site\ntitle = “The Miller Lab”   menus.toml  Location  config/_default/menus.toml\n  This is where you will control which items go on the top menu ribbon on your website.  * This is the default\n[[main]]\nname = “Demo”\nurl = “#hero”\nweight = 10\n[[main]]\nname = “Posts”\nurl = “#posts”\nweight = 20\n[[main]]\nname = “Projects”\nurl = “#projects”\nweight = 30\n[[main]]\nname = “Publications”\nurl = “#featured”\nweight = 40\n[[main]]\nname = “Courses”\nurl = “courses/”\nweight = 50\n[[main]]\nname = “Contact”\nurl = “#contact”\nweight = 60\n params.toml  Location  config/_default/params.toml\n  This is where you will control which items such as  Logo Contact Details (email, addresses, etc) Social Media Details Configuration of publication pages Marketing such as Google Analytics      Widgets in Hugo Academic Overview  The academic theme has lots of widgets; these are in your home folder; look fofr “active = “ and assign true or false depending on whether or not you want them “active = false” will hide the widget\n The Hugo project uses +++ to denote demarcation for TOML documents. It is a way for them to have a single text file that consists of TOML in the “frontmatter” (document meta-data), and a second “document” that is the body of page content.  Star  \nOcticon-start and Get Started Clicker\n Hero widget  This is the first widget worth adjusting\n This is where you change the title of the\n Within the TOML, you can add text using\n[cta_note]\nlabel = ‘Latest release’  [cta]\nurl = “https://sourcethemes.com/academic/docs/install/”\nlabel = “Get Started”\nicon_pack = “fas”\nicon = “download”\n[cta_alt]\nurl = “https://sourcethemes.com/academic/”\nlabel = “View Documentation”\n People Widget  Under content -\u0026gt; Home -\u0026gt; people.md\n This will allow you place a “Meet the Team” segment on the web page\n User_groups = [ ] is key\n Within the [ ] you should specify the names of the subfolders in the “authors”\n For example  Choose which groups/teams of users to display. Edit user_groups in each user’s profile to add them to one or more of these groups.\n user_groups = [“Fellows”, “Students”]\n Fellows and Students are the strings that you use in the _index.md files within each persons folder. “Authors” wd -\u0026gt; content -\u0026gt; authors What I did was create a subfolder of each person in “Authors” wd -\u0026gt; content -\u0026gt; authors For example wd -\u0026gt; content -\u0026gt; authors -\u0026gt; John-Doe  Then with the subfolder “John-Doe” the info for the site is placed in a .md or .Rmd file called _index.md or _index.Rmd. Then you list the person’s user-group accordingly and they will show up under that heading.\n Within the `_index.md file, use the following  authors:\n John-Doe\n  Then when you want to “tag” that person in say a post or a talk, you can write “- John-Doe” in under the authors: section of the YAML in that specific posting or talk   Talk Widget  To edit content go to content -\u0026gt; talk  Then edit  Example code that was embedded in default Talk widget page  Click on the Slides button above to view the built-in slides feature.\n   Slides can be added in a few ways:  Create slides using Academic’s\nSlides feature and link using slides parameter in the front matter of the talk file\n Upload an existing slide deck to static/ and link using url_slides parameter in the front matter of the talk file  Example from the miller lab website  I created a folder in “static” called “slides” Then I put the pdf of “MIG_3-1-19.pdf” in that folder\n Then in the index.md file under content-\u0026gt;talk-\u0026gt;MIG_3-1-19 I used the following\nurl_slides: “slides/MIG_3-1-19.pdf”\n I also removed “example” from line 29 Slides: “ ”\n This was key, otherwise it didn’t work  Embed your slides (e.g. Google Slides) or presentation video on this page using shortcodes.\n Further talk details can easily be added to this page using *Markdown* and $\\rm \\LaTeX$ math code.\n In the new folder you created you will need a index.md file and potentially a features.jpg\n Then make edits the index.md prn\n   Projects Widget  Md document is in the Home folder “projects.md”  content -\u0026gt; home -\u0026gt; projects.md\n  There is a built in mechanism to link your active projects The details for your project, however is located:  Content -\u0026gt; project Within thei “project” folder you can add new subfolders of the different ongoing projects  Toolbar  There is a tool bar feature that you can edit, e.g.\n[[content.filter_button]]\nname = “Data Science”\ntag = “data-science”\n  projects subfolder  As mentioned above, the actual descriptions of the projects are in Content -\u0026gt; project Here’s an example Content -\u0026gt; project -\u0026gt; data-science  With the “data-science” subfolder, there are two key files  Featured.jpg (the picture that will be feature)\nIndex.md  Index.md for projects  Here put the data you want in the YAML  Pay attention to  Tags: -data-science This will link this file to the tool bar in the projects page    Talks Widget Overview  “Presentations” in the menu ribbon are edited with the talks widget\n The content of those presentations is stored in the “talk” folder  Location of that folder: content/talk  Then create new folders in that “talk” folder, each of which represents a new presentation that you’ve given   Below is the canned Text that comes as a default abstract: Lorem ipsum dolor sit amet\naddress:\ncity: Stanford country: United States postcode: “94305” region: CA street: 450 Serra Mall\nall_day: false\nauthors: []\ndate: “2018-06-01T13:00:00Z”\ndate_end: “2018-06-01T15:00:00Z”\nevent: Academic Theme Conference\nevent_url: https://example.org\nfeatured: false\nimage:\ncaption: ‘Image credit: Unsplash’ focal_point: Right\nlinks: - icon: twitter icon_pack: fab name: Follow url: https://twitter.com/georgecushen location: Source Themes HQ math: true projects: - internal-project\npublishDate: “2017-01-01T00:00:00Z”\nslides: example\nsummary: An example talk using Academic’s Markdown slides feature.\ntags: []\ntitle: Example Talk\nurl_code: \u0026quot;\u0026quot;\nurl_pdf: \u0026quot;\u0026quot;\nurl_slides: \u0026quot;\u0026quot;\nurl_video: \u0026quot;\u0026quot;\n Click on the Slides button above to view the built-in slides feature.   Slides can be added in a few ways:\n Create slides using Academic’s Slides feature and link using slides parameter in the front matter of the talk file Upload an existing slide deck to static/ and link using url_slides parameter in the front matter of the talk file Embed your slides (e.g. Google Slides) or presentation video on this page using shortcodes.  Further talk details can easily be added to this page using *Markdown* and $\\rm \\LaTeX$ math code.\n   Other Pearls Links in Hugo  The default Hugo target directory for your built website is public/  Therefore, if you want to link to a file with this format [Merkel Cell Carcinoma tumor Registry](MCC_Registry.Rmd)\n Then the MCC_Registry.Rmd file must be in the public folder; this tripped me up for hours! This is considere a permalink    Netlify TOML  I Ran into a problem where I could not deploy from GitHub to Netlify\n I ran the error message into google and Alison Hill recommended that I create a netlify.toml\n https://alison.rbind.io/post/2019-02-19-hugo-netlify-toml/\n The key was addint the hugo_version to the latest version I was workin on (see below)\n Created netlify.toml in R in the workin directly (see content below)\n I then pushed it to GitHub and was all set! This is the code I got from Alison Hill’s website\n[build]\npublish = “public”\ncommand = “hugo”\n[context.production.environment]\nHUGO_VERSION = “0.59.1”\nHUGO_ENV = “production”\nHUGO_ENABLEGITINFO = “true”\n[context.branch-deploy.environment]\nHUGO_VERSION = “0.59.1”\n[context.deploy-preview.environment]\nHUGO_VERSION = “0.59.1”\n[context.deploy-preview]\ncommand = “hugo -b $DEPLOY_PRIME_URL –buildFuture”\n[context.branch-deploy]\ncommand = “hugo -b $DEPLOY_PRIME_URL –buildFuture”`\n   Adding images to your website  I added an img folder to the home folder and placed the file images in that folder\n Then within the Rmd file within the home folder I used this code ![](/img/DMM_pic.jpg)   Link to a PDF of your resume/CV from the menu  To enable, copy your resume/CV to static/files/cv.pdf and uncomment the lines below\n Direct the navigation bar to your CV by editing the menus.toml file  Wd -\u0026gt; config -\u0026gt; _default-\u0026gt; menus.toml [[main]]\nname = “CV”\nurl = “files/DMM_CV.pdf”\nweight = 70   sessionInfo() ## R version 3.6.1 (2019-07-05) ## Platform: x86_64-apple-darwin15.6.0 (64-bit) ## Running under: macOS Mojave 10.14.6 ## ## Matrix products: default ## BLAS: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRblas.0.dylib ## LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRlapack.dylib ## ## locale: ## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8 ## ## attached base packages: ## [1] stats graphics grDevices utils datasets methods base ## ## loaded via a namespace (and not attached): ## [1] compiler_3.6.1 magrittr_1.5 bookdown_0.16 tools_3.6.1 ## [5] htmltools_0.4.0 yaml_2.2.0 tinytex_0.17 Rcpp_1.0.3 ## [9] stringi_1.4.5 rmarkdown_1.17 blogdown_0.17.1 knitr_1.26 ## [13] stringr_1.4.0 digest_0.6.23 xfun_0.11 rlang_0.4.4 ## [17] evaluate_0.14   Posts There is folder in called “post” in the \u0026quot;content folder that allows you to post additional pages. Within that folder you can create various subfolders with their own index.md and featured.md. Of note, if you turn off the post widget, they can still show up on your people posting if you put in your YAML under authors: the appropriate label.\n  ","date":1577750400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1577750400,"objectID":"2d280187795748971faa1c4792967fe3","permalink":"/post/website-development-using-r/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/post/website-development-using-r/","section":"post","summary":"This working document is a rough user guide on how to create a website using R via a package called `blogdown`","tags":["Data Science","Blogdown","Rstuio","Hugo Academic"],"title":"Communicating CT Research via Website Development with R","type":"post"},{"authors":["Melms, J. C.","Vallabhaneni, S.","Mills, C. E.","Yapp, C.","Chen, J. Y.","Morelli, E.","Waszyk, P.","Kumar, S.","Deming, D.","Moret, N.","Rodriguez, S.","Subramanian, K.","Rogava, M.","Cartwright, A. N. R.","Luoma, A.","Mei, S.","Brinker, T. J.","David Michael Miller","Spektor, A.","Schadendorf, D.","Riggi, N.","Wucherpfennig, K. W.","Sorger, P. K.","Izar, B.","David Michael Miller"],"categories":null,"content":"Abstract: Melanoma patients resistant to RAF/MEK-inhibitors (RMi) are frequently resistant to other therapies, such as immune checkpoint inhibitors (ICI), and individuals succumb to their disease. New drugs that control tumor growth and favorably modulate the immune environment are therefore needed. We report that the small molecule CX-6258 has potent activity against both RMi sensitive (RMS) and resistant (RMR) melanoma cell lines. Haspin Kinase (HASPIN) was identified as a target of CX-6258. HASPIN inhibition resulted in reduced proliferation, frequent formation of micronuclei (MN), recruitment of cGAS and activation of the cGAS-STING-pathway. In murine models, CX-6258 induced a potent cGAS-dependent type-I-interferon response in tumor cells, increased IFNγ-producing CD8+ T-cells and reduced Treg frequency in vivo. HASPIN was more strongly expressed in malignant compared to healthy tissue and its inhibition by CX-6258 had minimal toxicity in ex vivo expanded human tumor-infiltrating lymphocytes (TILs), proliferating TILs and in vitro differentiated neurons, suggesting a potential therapeutic index for anti-cancer therapy. Furthermore, the activity of CX-6258 was validated in several Ewing sarcoma and multiple myeloma cell lines. Thus, HASPIN inhibition may overcome drug resistance in melanoma, modulate the immune environment and target a vulnerability in different cancer lineages.\n","date":1577577600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1577577600,"objectID":"267ce08494d164423047e0a748cf0cfd","permalink":"/publication/inhibition-of-haspin-kinase-promotes-cell-intrinsic-and-extrinsic-anti-tumor-activity/","publishdate":"2019-12-29T00:00:00Z","relpermalink":"/publication/inhibition-of-haspin-kinase-promotes-cell-intrinsic-and-extrinsic-anti-tumor-activity/","section":"publication","summary":"Inhibition of Haspin kinase may overcome drug resistance in melanoma, modulate the immune environment and target a vulnerability in different cancer lineages.","tags":["Melanoma","Cancer Research","Haspin"],"title":"Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1576242000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1576242000,"objectID":"ef9a0478941dfbd9e1a3abd8418fae37","permalink":"/talk/cumc_derm_lecture_regulatory_medicine-12-13-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_regulatory_medicine-12-13-19/","section":"talk","summary":"","tags":["Regulatory Medicine"],"title":"The Evolving Landscape of Regulatory Medicine in Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1576227600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1576227600,"objectID":"7295edbe20c9bad5b3db0c73400f47eb","permalink":"/talk/cumc_derm_lecture_melanoma-12-13-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_melanoma-12-13-19/","section":"talk","summary":"","tags":["Education","Melanoma","Dermatology"],"title":"Melanoma - Pathogenesis, Clinical Features, Diagnosis and Management","type":"talk"},{"authors":["Sophia Shalhout"],"categories":null,"content":"","date":1576150200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1576150200,"objectID":"5a20557ae8e1ab56ed8bac0d4ffee4b8","permalink":"/talk/szs_bch-12-12-19/","publishdate":"2019-12-12T14:00:00Z","relpermalink":"/talk/szs_bch-12-12-19/","section":"talk","summary":"","tags":null,"title":"Targeting the Hippo-YAP Pathway As a novel Therapeutic Approach in Cancer","type":"talk"},{"authors":["David Michael Miller"],"categories":[],"content":"The Massachusetts General Hospital Cancer Center and the Department of Dermatology are offering a 1-2 year research fellowship in cutaneous oncology. This position will provide a unique experience in cutaneous oncology and will include roles in clinical investigation and translational research.\nPlease see the attached PDF for more information.\n Cutaneous Oncology Research Fellow Posting\nCurrent Fellows\n  Sophia Shalhout, PhD   ","date":1575590400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1575590400,"objectID":"4526ba020a1beb0aab4c3c8702360bb0","permalink":"/post/cutaneous-oncology-research-fellow/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/post/cutaneous-oncology-research-fellow/","section":"post","summary":"A fellowship at MGH in Skin Cancer research","tags":["Regulatory Medicine","Biomarkers","Data Science","MCC Registry"],"title":"Cutaneous Oncology Research Fellow","type":"post"},{"authors":["Farees Saqlain"],"categories":null,"content":"","date":1575366300,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1575366300,"objectID":"643b30c679df8eb1cde7d043f9d992cf","permalink":"/talk/mgh_cut_onc_tumor_board_farees-12_03_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/mgh_cut_onc_tumor_board_farees-12_03_19/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","Education"],"title":"A Case of Bimodality Therapy for Merkel Cell Carcinoma","type":"talk"},{"authors":null,"categories":null,"content":"Overview We are involved with clinical studies to improve outcomes for patients with Skin Cancer\nClinical Trials in Merkel Cell Carcinoma Dr. Miller is the MGH site Principal Investigator for STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial\nClinical Trials in Melanoma Dr. Miller is a MGH sub-investigator for INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors\n","date":1574899200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1574899200,"objectID":"f7f611e169fc7fd88d9a770a2e8dc599","permalink":"/project/clinical-trials/","publishdate":"2019-11-28T00:00:00Z","relpermalink":"/project/clinical-trials/","section":"project","summary":"Investigating novel therapies for patients with advanced skin cancer","tags":["Clinical Trials"],"title":"Clinical Trials for Skin Cancer","type":"project"},{"authors":null,"categories":null,"content":"Overview We are investigating why patients respond - or fail to respond - to cancer therapies. Using biospecimen collection infrastructure at the Massachusetts General Hospital Cancer Center, we are collecting tissue on patients with advanced Skin Cancer in order to better understand why therapies work in certain patients, but not others.\n","date":1574812800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1574812800,"objectID":"d2f3a7d456c0ce19ff16c81be6c03b0a","permalink":"/project/biomarkers/","publishdate":"2019-11-27T00:00:00Z","relpermalink":"/project/biomarkers/","section":"project","summary":"Investigating why patients do or do not respond to cancer therapies","tags":["Biomarkers"],"title":"Biomarkers of Response and Resistance to Cancer Therapy","type":"project"},{"authors":null,"categories":null,"content":"Overview  We are developing Data Science Tools to faciliate Clinical and Translational Investigation We strive to create Data Science Pearls and Solutions for a wide variety of problems, such as communicating science and research through Website Development and FlexDashboards.  ","date":1574467200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1574467200,"objectID":"11ff52cef8439e197c8b6f0164015c02","permalink":"/project/data-science/","publishdate":"2019-11-23T00:00:00Z","relpermalink":"/project/data-science/","section":"project","summary":"Developing Data Science tools to facilitate clinical and translational research","tags":["Data Science"],"title":"Data Science Tool Development","type":"project"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1574146800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1574146800,"objectID":"3e6594335a9943238f8868bc231390c9","permalink":"/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/","section":"talk","summary":"","tags":["Clinical Trials","Squamous Cell Carcinoma"],"title":"Clinical Investigation in cSCC - Updates from ASCO and ESMO","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1571675400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1571675400,"objectID":"f6db97a257ddba215001931792fe3272","permalink":"/talk/moffit_10-21-19/","publishdate":"2019-11-12T16:00:00Z","relpermalink":"/talk/moffit_10-21-19/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","MCC Registry"],"title":"Project Data Sphere and Ongoing Multi-Institutional Database Efforts","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1570460400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1570460400,"objectID":"329dbbf9f15e243442a7ee73a2fe00fb","permalink":"/talk/sanofi_expert_series/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/sanofi_expert_series/","section":"talk","summary":"","tags":["Squamous Cell Carcinoma","Clinical Trials"],"title":"2019 ASCO IO Abstracts Review","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview The Merkel Cell Carcinoma Patient Registry is a multi-institutional collaborative effort that is collecting data on outcomes and events in MCC patients. MCC is the prototypical rare tumor, and this Registry aims to develop new methodologies that will enable investigators to examine real world data in real time. Deliverables from the Registry include: (i) precise patient risk stratification, (ii) real-world data for drug development programs, (iii) identification of optimal sequence and combinations therapies, (iv) uncovering low-incidence toxicities and (v) revelations about best practices, (vi) and the generation of novel testable hypotheses.\n","date":1567330200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1567330200,"objectID":"f460f8d404f9d3f6f650f27d44fc2863","permalink":"/funding/pds-award/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/funding/pds-award/","section":"funding","summary":"Merkel Cell Carcinoma Patient Registry","tags":["MCC Registry"],"title":"Project Data Sphere’s Mentoring Award in Oncology, Advanced Analytics and Regulatory Science","type":"funding"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1566549000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1566549000,"objectID":"e476eec1837db8e33c33e789b0c9b169","permalink":"/talk/medical_education_program_on_melanoma_management_nmsc-8-23-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/medical_education_program_on_melanoma_management_nmsc-8-23-19/","section":"talk","summary":"","tags":["Dermatology","Merkel Cell Carcinoma","Medical Oncology","Education","Squamous Cell Carcinoma"],"title":"Work Up and Management of Non-Melanoma Skin Cancer","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1566547200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1566547200,"objectID":"47988a007f3828355a7944623b150395","permalink":"/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/","publishdate":"2019-11-29T18:00:00Z","relpermalink":"/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/","section":"talk","summary":"","tags":["Melanoma","Education","Dermatology"],"title":"Diagnosis and Initial Management of Melanoma","type":"talk"},{"authors":["David M. Miller MD","PhD","FAAD"],"categories":null,"content":"","date":1566291600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1566291600,"objectID":"729ada453bccecfa3a2912c92feeb24a","permalink":"/talk/fda_mini_symposium_on_drug_repurposing-8-20-19/","publishdate":"2019-11-12T18:00:00Z","relpermalink":"/talk/fda_mini_symposium_on_drug_repurposing-8-20-19/","section":"talk","summary":"","tags":["MCC Registry","Regulatory Medicine"],"title":"MCC Patient Registry","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1564731900,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1564731900,"objectID":"b0658a1cf3df333b0a6feb9f53cb316e","permalink":"/talk/harvard_derm_resident_lecture_melanoma-part_2-08-02-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_melanoma-part_2-08-02-19/","section":"talk","summary":"","tags":["Melanoma","Education","Dermatology","Medical Oncology"],"title":"Melanoma - Work Up and Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1564645500,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1564645500,"objectID":"5125e72935548e8396e7abf70c47c358","permalink":"/talk/harvard_derm_resident_lecture_melanoma-part_1-08-01-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_melanoma-part_1-08-01-19/","section":"talk","summary":"","tags":["Melanoma","Education","Dermatology","Medical Oncology"],"title":"Melanoma - Epidemiology and Pathogenesis","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1560841200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1560841200,"objectID":"0844b95084f20a5f7270fcf951291f41","permalink":"/talk/mgh_meei_nmsc_program_research_meeting-06_18_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/mgh_meei_nmsc_program_research_meeting-06_18_19/","section":"talk","summary":"","tags":["MCC Registry","Merkel Cell Carcinoma"],"title":"Merkel Cell Carcinoma Tumor Registry","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1560158100,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1560158100,"objectID":"2aa46025fa26fdced0af0645a0497982","permalink":"/talk/mgh_melanoma_np_approach_to_skin_biopsy-06_10_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/mgh_melanoma_np_approach_to_skin_biopsy-06_10_19/","section":"talk","summary":"","tags":["Dermatology"],"title":"Approach to the Skin Biopsy","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1559500200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1559500200,"objectID":"31d2104fda73f32356ccc9dcae02c646","permalink":"/talk/scout_6-2-19/","publishdate":"2019-11-04T00:00:00Z","relpermalink":"/talk/scout_6-2-19/","section":"talk","summary":"","tags":["MCC Registry","Merkel Cell Carcinoma"],"title":"Project Data Sphere \u0026 MCC patient Registry- From Promise to Prototype to Patient","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1558375200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1558375200,"objectID":"9b1ae530c24e7452a87b70f49ce14bc8","permalink":"/talk/harvard_derm_interest_group-05-20-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_interest_group-05-20-19/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Clinical and Translational Research in Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1558364400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1558364400,"objectID":"18b942653ceab76bbdf658db80cbbad8","permalink":"/talk/bidmc_board_prep-05-20-19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_board_prep-05-20-19/","section":"talk","summary":"","tags":["Education","Dermatology","Melanoma","Merkel Cell Carcinoma","Squamous Cell Carcinoma"],"title":"Cutaneous Oncology Board Preparation","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1557252000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1557252000,"objectID":"62ab195fd0f5d2878a7848d600785648","permalink":"/talk/unmc_5_7_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/unmc_5_7_19/","section":"talk","summary":"","tags":["regulatory-medicine"],"title":"Regulatory Medicine in Cutaneous Oncology","type":"talk"},{"authors":null,"categories":null,"content":"Overview Dr. Miller and Dr. Michael K. Wong co-chair a Project Data Sphere (PDS)-led Task Force of key opinion leaders who are working together to develop a multi-institutional registry for patients with Merkel Cell Carcinoma (MCC).\nThe Merkel Cell Carcinoma Tumor Registry is a collaborative effort that is collecting data on outcomes and events in MCC patients. Deliverables from the MCC Registry include: (i) improved patient risk stratification, (ii) identification of optimal sequence and combinations therapies, (iii) uncovering low-incidence toxicities, (iv) revelations about best practices, (v) novel hypotheses, and (vi) real-world data for drug development programs.\nThe MCC Task Force is composed of members from academic medical centers, the National Institutes of Health, the pharmaceutical industry and the U.S Food and Drug Administration. Project Data Sphere, LLC provides a secure, open-access data sharing platform and comprehensive support to optimize research performance and ensure rigorous and timely results. The Registry is currently in Part 1 of a two-stage Pilot project, in which we are collecting MCC outcomes at the MGH and the Dana-Farber/Harvard Cancer Center to clarify what data elements to collect, how to code the data and how to standardize the information collection in a way to facilitate analysis.\n","date":1556323200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1556323200,"objectID":"bc9f6e8cb1251427fcda18327d84bafb","permalink":"/project/mcc-registry/","publishdate":"2019-04-27T00:00:00Z","relpermalink":"/project/mcc-registry/","section":"project","summary":"Developing a multi-institutional Patient Registry.","tags":["MCC Registry","Merkel Cell Carcinoma"],"title":"Merkel Cell Carcinoma Patient Registry","type":"project"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1555578000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1555578000,"objectID":"8a71f71bd10743e9e4ba2dff5cecc932","permalink":"/talk/gw_derm_resident_lecture_mcc-04-18-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/gw_derm_resident_lecture_mcc-04-18-19/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","Education","Dermatology","Medical Oncology"],"title":"Merkel Cell Carcinoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1554195600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1554195600,"objectID":"4bfb94d035347bb703f0a31dfa2e1805","permalink":"/talk/mgh_cut_on_lect_series_reg_med-04_02_19/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/mgh_cut_on_lect_series_reg_med-04_02_19/","section":"talk","summary":"","tags":["Regulatory Medicine","Dermatology","Education","Medical Oncology"],"title":"Regulatory Medicine in Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1553497200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1553497200,"objectID":"bfdd99271a126882e5db85504b4c3a72","permalink":"/talk/harvard_derm_resident_journal_club-03-25-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_journal_club-03-25-19/","section":"talk","summary":"","tags":["Education","Melanoma","Medical Oncology","Dermatology"],"title":"Neoadjuvant PD-1 Blockade in Resectable Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1551463200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1551463200,"objectID":"3e800ccd50f59295cbd4c902ecddfa95","permalink":"/talk/mig_3-1-19/","publishdate":"2017-01-01T00:00:00Z","relpermalink":"/talk/mig_3-1-19/","section":"talk","summary":"","tags":["MCC Registry","Merkel Cell Carcinoma"],"title":"Project Data Sphere \u0026 MCC patient Registry- From Promise to Prototype to Patient","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1550818800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1550818800,"objectID":"b45cff7b9a9b491867be25d7871d225b","permalink":"/talk/harvard_derm_resident_lecture_sezary-02-22-19/","publishdate":"2019-12-01T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_sezary-02-22-19/","section":"talk","summary":"","tags":["Sezary Syndrome","Education","Dermatology"],"title":"Sezary Syndrome Part 2 - Diagnosis and Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1550214000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1550214000,"objectID":"0dbed02b3b71141b9fa95660d72e51a2","permalink":"/talk/harvard_derm_resident_lecture_sezary-02-15-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_sezary-02-15-19/","section":"talk","summary":"","tags":["Education","Dermatology","Sezary Syndrome"],"title":"Sezary Syndrome Part 1 - Pathogenesis and Clinical Features","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;\n   ","date":1549611900,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1549611900,"objectID":"833cf0fe2f5474761056478aea1bb3c1","permalink":"/talk/harvard_derm_resident_mgods-02-08-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_mgods-02-08-19/","section":"talk","summary":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;","tags":["mGODS","Dermatology","Education","Medical Oncology"],"title":"mGODS - Monoclonal Gammopathies Of Dermatological Significance","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1547735400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1547735400,"objectID":"93eb5efa7b5796c04e3122d45b7a9bed","permalink":"/talk/gw_derm_resident_lecture_sezary-01-17-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/gw_derm_resident_lecture_sezary-01-17-19/","section":"talk","summary":"","tags":["Sezary Syndrome"],"title":"Sezary Syndrome","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS    (https://www.themillerlab.io/talk/harvard_derm_resident_mgods-01-31-17/) \u0026#x21a9;\u0026#xfe0e;\n   ","date":1547730000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1547730000,"objectID":"5562f2d23c04c526071a7364489731d7","permalink":"/talk/gw_derm_resident_lecture_mgods-01-17-19/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/gw_derm_resident_lecture_mgods-01-17-19/","section":"talk","summary":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS    (https://www.","tags":["mGODS","Dermatology","Education","Medical Oncology"],"title":"mGODS - Monoclonal Gammopathies of Dermatological Signficance","type":"talk"},{"authors":["Klebanov, Nikolai","Gunasekera, Nicole S","Lin, William M","Hawryluk, Elena B","David Michael Miller","Reddy, Bobby Y","Christman, Mitalee P","Beaulieu, Derek","Rajadurai, Suvithan","Duncan, Lyn M","Sober, Arthur J","Tsao, Hensin"],"categories":null,"content":"Abstract BACKGROUND: Melanoma can mimic other cutaneous lesions, but the full spectrum and prevalence of these morphologic variants remain largely unknown.\nOBJECTIVE: To classify nonacral cutaneous melanomas into distinct morphologic clusters and characterize clusters\u0026rsquo; clinicopathologic features.\nMETHODS: All pathologic melanoma diagnoses (occurring during 2011-2016) were reviewed for routine prebiopsy digital photographs (n = 400). Six dermatologists independently assigned lesions into 1 of 14 diagnostic classes on the basis of morphology. Image consensus clusters were generated by K-means; clinicopathologic features were compared with analysis of variance and chi(2).\nRESULTS: Five morphologic clusters were identified: typical (n = 136), nevus-like (n = 81), amelanotic/nonmelanoma skin cancer (NMSC)-like (n = 70), seborrheic keratosis (SK)-like (n = 68), and lentigo/lentigo maligna (LM)-like (n = 45) melanomas. Nevus-like melanomas were found in younger patients. Nevus-like and lentigo/LM-like melanomas tended to be thinner and more likely identified on routine dermatologic examinations. NMSC-like melanomas were tender, thicker, more mitotically active, and associated with prior NMSC. Typical and SK-like melanomas had similar clinicopathologic features. LIMITATIONS: Cluster subdivision yielded diminished sample sizes. Visual assignment was performed without clinical context.\nCONCLUSION: When primary cutaneous melanomas were assigned into diagnostic groups and subjected to novel consensus clustering, recurrent morphologic patterns emerged. The spectrum of these morphologies was unexpectedly diverse, which might have implications for visual training and possibly clinical diagnosis.\n","date":1546300800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1546300800,"objectID":"89662349640652a366eaca2e9c79d4ab","permalink":"/publication/clinical-spectrum-of-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/clinical-spectrum-of-melanoma/","section":"publication","summary":"The clinical spectrum of cutaneous melanoma morphology is surprisingly diverse","tags":["Melanoma"],"title":"Clinical spectrum of cutaneous melanoma morphology.","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1545208200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1545208200,"objectID":"230559a6ac30bd9d383860d106e3679f","permalink":"/talk/bidmc_hem_onc_grand_rounds_12_19-18/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_hem_onc_grand_rounds_12_19-18/","section":"talk","summary":"","tags":["Regulatory Medicine","Clinical Trials"],"title":"Reducing M\u0026M in M\u0026M - Strategies to improve Morbidity and Mortality in Melanoma and Merkel cell carcinoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1541768400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1541768400,"objectID":"524d860f8ff2bbb9b45ab0cd42061725","permalink":"/talk/cumc_derm_lecture_regulatory_medicine-11-09-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_regulatory_medicine-11-09-18/","section":"talk","summary":"","tags":["Regulatory Medicine","Medical Oncology","Dermatology"],"title":"FDA Action in Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1541754000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1541754000,"objectID":"34e2281219fa9cd9db1a2e317208605c","permalink":"/talk/cumc_derm_lecture_sezary-11-09-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_sezary-11-09-18/","section":"talk","summary":"","tags":["Education","Dermatology","Sezary Syndrome"],"title":"Sezary Syndrome","type":"talk"},{"authors":["David Michael Miller","Trowbridge, R. M.","Desai, A.","Drews, R. E."],"categories":null,"content":"Abstract BACKGROUND: Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized, including combining immune checkpoint blockade (ICB) with oncolytic herpes viruses. Talimogene laherparepvec (T-VEC) is the first genetically modified oncolytic viral therapy (OVT) approved for the treatment of recurrent and unresectable melanoma. The use of IO in patients with concomitant malignancies and/or compromised immune systems is limited due to systematic exclusion from clinical trials. For example, a single case report of a solid organ transplant patient successfully treated with T-VEC for metastatic melanoma has been reported. Furthermore, the use of ICB in T-cell malignancies is limited and paradoxical worsening has been described. To our knowledge, this is the first report of dual ICB/T-VEC being administered to a patient with concurrent primary cutaneous anaplastic large cell lymphoma (pcALCL) and melanoma\nCASE PRESENTATION: Here we present the case of a patient with concomitant primary cutaneous ALCL and metastatic melanoma, progressing on anti-programmed death (PD)-1 therapy, who developed Kaposi's varicelliform eruption after receiving the first dose of Talimogene laherparepvec.\nCONCLUSION: This case highlights the complexities of care of patients with coexistent cancers, demonstrates rapid progression of primary cutaneous ALCL on nivolumab and introduces a novel adverse effect of Talimogene laherparepvec.\n","date":1541030400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1541030400,"objectID":"5b96fa9d6598bcd947dc8ad673ff8630","permalink":"/publication/eczema-tvecium/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/eczema-tvecium/","section":"publication","summary":"Novel finding of Eczema TVecium in a patient with melanoma and ALCL treated with T-VEC","tags":["Dermatology","Melanoma","T-VEC","Kaposi's Varicelliform Eruption"],"title":"Eczema Tvecium","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1540209600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1540209600,"objectID":"1e0160e6a466f31d4b9a061db465d49b","permalink":"/talk/fda_registries_task_force-10-22-18/","publishdate":"2019-12-04T18:00:00Z","relpermalink":"/talk/fda_registries_task_force-10-22-18/","section":"talk","summary":"","tags":["MCC Registry","Merkel Cell Carcinoma"],"title":"PDS MCC Tumor Registry","type":"talk"},{"authors":["David M. Miller MD","PhD","FAAD"],"categories":null,"content":"","date":1540202400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1540202400,"objectID":"707808e8a829cd185b3d8fa26be12ef8","permalink":"/talk/fda_oce_grand_rounds-10-22-18/","publishdate":"2019-12-04T18:00:00Z","relpermalink":"/talk/fda_oce_grand_rounds-10-22-18/","section":"talk","summary":"","tags":["Regulatory Medicine","MCC Registry"],"title":"FDA Action in Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1535108400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1535108400,"objectID":"34945e7482734c983cfa4a951e5eddb8","permalink":"/talk/cumc_derm_lecture_innate_immunity-08-24-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_innate_immunity-08-24-18/","section":"talk","summary":"","tags":["Education","Dermatology","Immunology"],"title":"PAMPs, DAMPs and Dermatology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1535101200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1535101200,"objectID":"1640613bcfa66da3f1934f8268a83ccd","permalink":"/talk/cumc_derm_lecture_t_cell_biology-08-24-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_t_cell_biology-08-24-18/","section":"talk","summary":"","tags":["Education","Dermatology","Immunology"],"title":"TCRs, Tsubs and dHSRs - T-cell Immunity for the Dermatologist","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1533020400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1533020400,"objectID":"c7105199b0d6841ab9915348d430a088","permalink":"/talk/harvard_derm_resident_lecture_melanoma-07-31-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_melanoma-07-31-18/","section":"talk","summary":"","tags":["Melanoma","Dermatology","Education","Medical Oncology"],"title":"Introduction to Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.\n","date":1530437400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1530437400,"objectID":"0ed56fb833befcc7ad4757f51159ef65","permalink":"/funding/ecog-acrin/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/funding/ecog-acrin/","section":"funding","summary":"A Novel JAK1 Inhibitor to Overcome BRAF/MEK Inhibitor Resistance in V600-BRAF Mutant Melanoma","tags":["Clinical Trials"],"title":"ECOG ACRIN Paul Carbone, MD Fellowship Award","type":"funding"},{"authors":["Eliades, P.","Abraham, B. J.","Ji, Z.","David Michael Miller","Christensen, C. L.","Kwiatkowski, N.","Kumar, R.","Njauw, C. N.","Taylor, M.","Miao, B.","Zhang, T.","Wong, K. K.","Gray, N. S.","Young, R. A.","Tsao, H."],"categories":null,"content":"Abstract Cutaneous melanoma is an aggressive tumor that accounts for most skin cancer deaths. Among the physiological barriers against therapeutic success is a strong survival program driven by genes such as MITF that specify melanocyte identity, a phenomenon known in melanoma biology as lineage dependency. MITF overexpression is occasionally explained by gene amplification, but here we show that super-enhancers are also important determinants of MITF overexpression in some melanoma cell lines and tumors. Although compounds that directly inhibit MITF are unavailable, a covalent *CDK7 inhibitor, THZ1, has recently been shown to potently suppress the growth of various cancers through the depletion of master transcription-regulating oncogenes and the disruption of their attendant super-enhancers. We also show that melanoma cells are highly sensitive to CDK7 inhibition both in vitro and in vivo and that THZ1 can dismantle the super-enhancer apparatus at MITF and SOX10 in some cell lines, thereby extinguishing their intracellular levels. Our results show a dimension to MITF regulation in melanoma cells and point to CDK7 inhibition as a potential strategy to deprive oncogenic transcription and suppress tumor growth in melanoma.\n","date":1530403200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1530403200,"objectID":"af03e1e3746f440b1973c3523789623f","permalink":"/publication/cdk7/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/cdk7/","section":"publication","summary":"CDK7 inhibition is a potential strategy to deprive oncogenic transcription and suppress tumor growth in melanoma.","tags":["Melanoma","CDK7","MITF","Super Enhancers"],"title":"Role of CDK7 in Melanoma","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1528959600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1528959600,"objectID":"5f4f2969b9c54b056fbea0e8c30e445e","permalink":"/talk/meei_grand_rounds-06_14_18/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/meei_grand_rounds-06_14_18/","section":"talk","summary":"","tags":["Education","Merkel Cell Carcinoma","Dermatology","Medical Oncology"],"title":"Merkel Cell Carcinoma - Updates in Diagnosis and Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1526648400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1526648400,"objectID":"518ecf51ab171b97b7d776aded38e0e5","permalink":"/talk/cumc_derm_lecture_mcc-05-18-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_mcc-05-18-18/","section":"talk","summary":"","tags":["Education","Merkel Cell Carcinoma","Dermatology"],"title":"Merkel Cell Carcinoma","type":"talk"},{"authors":["David M. Miller MD","PhD","FAAD"],"categories":null,"content":"","date":1526641200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1526641200,"objectID":"289002a960d1aa74c016a4d9a246e84d","permalink":"/talk/cumc_derm_lecture_melanoma-05-18-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_melanoma-05-18-18/","section":"talk","summary":"","tags":["Education","Melanoma"],"title":"Introduction to Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1526635800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1526635800,"objectID":"0eba62924d150e24e3930e04aa84acb9","permalink":"/talk/cumc_derm_lecture_cancer_biology-05-18-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_cancer_biology-05-18-18/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"The Biology of Cutaneous Oncology","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;\n   ","date":1526630400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1526630400,"objectID":"3ba7e1b8f5f0ff9b6c04c08eb6a011f6","permalink":"/talk/cumc_derm_lecture_mgods-05-18-18/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_mgods-05-18-18/","section":"talk","summary":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;","tags":["mGODS","Dermatology","Education","Medical Oncology"],"title":"mGODS - Monoclonal Gammopathies of Dermatological Signficance","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1525771800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1525771800,"objectID":"e88e393a2eba96c87c0a4b78ee69711c","permalink":"/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/","publishdate":"2019-12-01T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/","section":"talk","summary":"","tags":["Dermatology","Immunology","Education"],"title":"PAMPs DAMPs and Dermatology - Innate Immunity for the Dermatologist","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.\n","date":1514799000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1514799000,"objectID":"e002fbf933de7c4b87e50131dd2ef7b7","permalink":"/funding/asa/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/funding/asa/","section":"funding","summary":"JAK1 Inhibition to Overcome BRAF/MEK Inhibitor Resistance in V600-BRAF Mutant Melanoma","tags":["Clinical Trials"],"title":"American Skin Association Research Grant","type":"funding"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;\n   ","date":1513675800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1513675800,"objectID":"9c4dd43566ee136269666d12e8e97fba","permalink":"/talk/harvard_derm_resident_mgods-12-19-17/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_mgods-12-19-17/","section":"talk","summary":"Overview  In this lecture we review mGODS: Monoclonal Gammopathies of Dermatological Significance1, an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS     First described \u0026#x21a9;\u0026#xfe0e;","tags":["Dermatology","Medical Oncology","Education","mGODS"],"title":"mGODS - Monoclonal Gammopathies Of Dermatological Significance","type":"talk"},{"authors":["David Michael Miller","Xin Gao"],"categories":null,"content":"","date":1513238400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1513238400,"objectID":"4dae2655c9ad3a5d12a0bee1bffeb725","permalink":"/talk/bidmc_topics_in_oncology-12_14-17/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_topics_in_oncology-12_14-17/","section":"talk","summary":"","tags":null,"title":"No Claims No Gains - Why You Need to Know the Business Side of Medicine","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1512723600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1512723600,"objectID":"46cacb663de618e46685c01270043e1b","permalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-12-08-2017/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-12-08-2017/","section":"talk","summary":"","tags":["Dermatology","Education"],"title":"Common Primary Care Dermatoses","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1511260200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1511260200,"objectID":"60182d90de3ad0407b26f01786bd4f95","permalink":"/talk/harvard_derm_resident_lecture_sezary-11-21-17/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_sezary-11-21-17/","section":"talk","summary":"","tags":["Dermatology","Sezary Syndrome","Education","Medical Oncology"],"title":"Sezary Syndrome","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1509436800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1509436800,"objectID":"a9c5f8df0b7e70dec530df1218720684","permalink":"/talk/bidmc_journal_club_10-31-17/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_journal_club_10-31-17/","section":"talk","summary":"","tags":["Melanoma","Education"],"title":"Nivolumab as Adjuvant Therapy for Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1507280400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1507280400,"objectID":"912a97e4ea86cefb2ac9f8957f2533f3","permalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-10-06-2017/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-10-06-2017/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Common Primary Care Dermatoses","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1506070800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1506070800,"objectID":"a3770c355554e24c0047b2559526ecb8","permalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-09-22-2017/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-09-22-2017/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Common Primary Care Dermatoses","type":"talk"},{"authors":["David Michael Miller","Faulkner-Jones, B. E.","Stone, J. R.","Drews, R. E."],"categories":null,"content":"Abstract: Although most cases of metastatic cutaneous Squamous Cell Carcinoma mCSCC can be cured with local therapy, up to 8,000 deaths occur each year. With no US Food and Drug Administration-approved options available for mcSCC, common approaches include platinum- based chemotherapy and off-label cetuximab. These strategies lack durability, and overall survival for mcSCC is only 10.9 months. Here we report a complete pathologic response after 4 cycles of nivolumab and the antieCTLA-4 antibody, ipilimumab, in a patient with mCSCC.\n","date":1504828800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1504828800,"objectID":"7a1366a3638d82d540d8d9bfe385cbe8","permalink":"/publication/cr-ipi-nivo-scc/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/cr-ipi-nivo-scc/","section":"publication","summary":"We report a path CR in a patient with mCSCC treated with Ipi/Nivo","tags":["Squmaous Cell Carcinoma","Immunotherapy"],"title":"A Complete Response in cSCC with Ipi/Nivo","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1502793000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1502793000,"objectID":"df4243ddce6a27032a77e25af55f9352","permalink":"/talk/harvard_derm_resident_lecture_melanoma-08-15-17/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_melanoma-08-15-17/","section":"talk","summary":"","tags":["Melanoma","Dermatology","Education","Medical Oncology"],"title":"Introduction to Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1496142000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1496142000,"objectID":"7e93bbb8b463e571127b0727179bae5a","permalink":"/talk/harvard_derm_resident_lecture_sezary-05-30-17/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_lecture_sezary-05-30-17/","section":"talk","summary":"","tags":["Sezary Syndrome","Education","Dermatology","Medical Oncology"],"title":"Sezary Syndrome","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1495611900,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1495611900,"objectID":"21a518a6fcb94d427daf16ae8d45ad5d","permalink":"/talk/bidmc_hematology_sezary-05-24-17/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_hematology_sezary-05-24-17/","section":"talk","summary":"","tags":["Sezary Syndrome","Education"],"title":"Sezary Syndrome","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":" Somatic driver mutations in melanoma.\n","date":1495152000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1495152000,"objectID":"cd2644f163d5661546e1f6b98d21ddbf","permalink":"/publication/somatic-drivers-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/somatic-drivers-melanoma/","section":"publication","summary":"Somatic driver mutations in melanoma.","tags":[],"title":"Somatic Driver Mutations in Melanoma","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1493712000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1493712000,"objectID":"cce37a97c54261b79c119047fa786e7a","permalink":"/talk/bidmc_journal_club_05-02-17/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_journal_club_05-02-17/","section":"talk","summary":"","tags":null,"title":"Avelumab for Patients with Merkel Cell Carcinoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview  In this lecture we review the most common dermatoses that result from monoclonal gammopathies. The lecture also introduces the term mGODS: Monoclonal Gammopathies of Dermatological Significance as an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS  ","date":1485856800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1485856800,"objectID":"6290cfacdac471e0bb2a5cae756cdd69","permalink":"/talk/harvard_derm_resident_mgods-01-31-17/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/harvard_derm_resident_mgods-01-31-17/","section":"talk","summary":"Overview  In this lecture we review the most common dermatoses that result from monoclonal gammopathies. The lecture also introduces the term mGODS: Monoclonal Gammopathies of Dermatological Significance as an umbrella term that captures diseases such as Cutaneous Amyloidoses, Scleromyxedema, Acquired Cutis Laxa, Mixed Cryoglobulinemia, Nodular Amyloidoses, PEOMS syndrome, Necrobiotic Xanthogranuloma, Schnitzler's Syndrome etc.  Learning Objectives  Provide an overview of plasma cell dyscrasias Introduce the concept of mGODS Review techniques to detect and identify monoclonal roteins Revew how to work up paraproteins Provide an overview of MGUS  ","tags":["mGODS","Dermatology","Education","Medical Oncology"],"title":"mGODS - Monoclonal Gammopathies Of Dermatological Significance","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":" A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.\n","date":1467417600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1467417600,"objectID":"a46733953ae86a25c08aad3062118577","permalink":"/publication/multi-cdk-inhibitor-in-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/multi-cdk-inhibitor-in-melanoma/","section":"publication","summary":"A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.","tags":[],"title":"A novel multi-CDK inhibitor in Melanoma","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1465545600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1465545600,"objectID":"8ae8402bd948702afe469797c81bde95","permalink":"/talk/bidmc_hematology_gvhd-06_10-16/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_hematology_gvhd-06_10-16/","section":"talk","summary":"","tags":null,"title":"Scratching the Surface of Acute Graft vs. Host Disease","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":" Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.\n","date":1464739200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1464739200,"objectID":"c8be30351135ab84835d414343006b0c","permalink":"/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/","section":"publication","summary":"Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.","tags":[],"title":"Molecularly Targeted Therapies and Immunotherapies For Melanoma","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" Cyclin-dependent kinases as therapeutic targets in melanoma.\n","date":1463443200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1463443200,"objectID":"b53c27a1052820bb8e1360af531219ea","permalink":"/publication/cdk-inhibotrs-in-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/cdk-inhibotrs-in-melanoma/","section":"publication","summary":"Cyclin-dependent kinases as therapeutic targets in melanoma.","tags":[],"title":"CDKs as Therapeutic Targets in Melanoma","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" Commentary: Molecular Testing in Melanoma.\n","date":1462060800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1462060800,"objectID":"297ef470622059a03487a2599013ecef","permalink":"/publication/molecular-testing-in-melanoma/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/molecular-testing-in-melanoma/","section":"publication","summary":"Commentary: Molecular Testing in Melanoma.","tags":[],"title":"Molecular testing in melanoma","type":"publication"},{"authors":null,"categories":null,"content":"Overview Dr. Miller has been teaching nurses, medical students and residents for over 15 years\n","date":1461715200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1461715200,"objectID":"06eee484a7f3669242acc59a2f2ea4e2","permalink":"/project/clinical-educator/","publishdate":"2016-04-27T00:00:00Z","relpermalink":"/project/clinical-educator/","section":"project","summary":"Participating in the education of tomorrow's clinicians","tags":["Education"],"title":"Clinical Educator","type":"project"},{"authors":null,"categories":null,"content":"Overview We are evaluating the evolving landscape of regulatory medicine in Cutaneous Oncology and Dermatology\n","date":1461715200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1461715200,"objectID":"1dc892e533f6555cb8251388cdace8ef","permalink":"/project/regulatory-medicine/","publishdate":"2016-04-27T00:00:00Z","relpermalink":"/project/regulatory-medicine/","section":"project","summary":"Evaluating the evolving landscape of regulatory medicine in Cutaneous Oncology and Dermatology","tags":["Regulatory Medicine"],"title":"Evolving Landscape of Regulatory Medicine","type":"project"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1458919800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1458919800,"objectID":"e3f0e484b9100db18f68315da6d8729e","permalink":"/talk/bwh_derm_directive_approach_to_purpura-03-25-16/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_derm_directive_approach_to_purpura-03-25-16/","section":"talk","summary":"","tags":["Education"],"title":"Approach to Purpura","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1454081400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1454081400,"objectID":"165a48bc1fe8f68d16d91273c793a8d5","permalink":"/talk/bwh_derm_directive_red_leg-01-29-16/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_derm_directive_red_leg-01-29-16/","section":"talk","summary":"","tags":["Education","Dermatology","Cellulitis"],"title":"The Red Leg","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1452844800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1452844800,"objectID":"46026bc0123aa596da1f0cb8bbc0a202","permalink":"/talk/bidmc_hematology_mf-01-15-16/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_hematology_mf-01-15-16/","section":"talk","summary":"","tags":["Mycosis Fungoides","Education"],"title":"Mycosis Fungoides - Clinical Features, Diagnosis \u0026 Management","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1449129600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1449129600,"objectID":"6e07d66c5463deb33783dc2a725f85a9","permalink":"/talk/bidmc_topics_in_oncology-12_03-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bidmc_topics_in_oncology-12_03-15/","section":"talk","summary":"","tags":["Merkel Cell Carcinoma","Education"],"title":"Merkel Cell Carcinoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1446823800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1446823800,"objectID":"0f2c29a3ca8c8e11b1dfc2e9155fc896","permalink":"/talk/bwh_derm_directive_cellulitis_and_its_mimics-11-06-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_derm_directive_cellulitis_and_its_mimics-11-06-15/","section":"talk","summary":"","tags":["Education","Cellulitis","Dermatology"],"title":"Cellulitis and Its Mimics","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1444404600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1444404600,"objectID":"c34ccc203477a05c9e5b051eaa7e694e","permalink":"/talk/bwh_derm_directive_vesiculobullous_eruptions-10-09-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_derm_directive_vesiculobullous_eruptions-10-09-15/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Vesiculobullous Eruptions","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1437728400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1437728400,"objectID":"93e5914109395858cd32a0b1454e6fc5","permalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-07-24-2015/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_amb_lecture_common_prim_care_derm-07-24-2015/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Common Primary Care Dermatoses","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1434560400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1434560400,"objectID":"741f6665186a69d57e341715786c9dfe","permalink":"/talk/hms-md-phd-lhb-grand-rounds-6-17-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/hms-md-phd-lhb-grand-rounds-6-17-15/","section":"talk","summary":"","tags":["Education","Harvard Medical School","MD/PhD Program"],"title":"A Case of Early-Onset Dementia","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1433142000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1433142000,"objectID":"6226a38f92fb95a6d2a27902a523eaf3","permalink":"/talk/bwh_im_morning_report-04-15-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_morning_report-04-15-15/","section":"talk","summary":"","tags":["Education","Acute Generalized Exanthematous Pustulosis","Dermatology","Brigham and Women's Hospital"],"title":"A Patient with Fever and Rash","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1429081200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1429081200,"objectID":"b0de130ebeede9c05bf94700641e23a6","permalink":"/talk/bwh_im_intern_report-6-1-15/","publishdate":"2019-11-28T04:00:00Z","relpermalink":"/talk/bwh_im_intern_report-6-1-15/","section":"talk","summary":"","tags":["Education","Paniculitis","Dermatology","Scabies","Internal Medicine","Brigham and Women's Hospital"],"title":"A Painful Rash","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1427446800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1427446800,"objectID":"4bdc64be4083c6abdc37665e6b0e017c","permalink":"/talk/cumc_derm_lecture_melanoma-03-27-15/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_melanoma-03-27-15/","section":"talk","summary":"","tags":["Melanoma","Dermatology","Education"],"title":"Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1422459000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1422459000,"objectID":"27736e8e08b188c4f78ff2448d5b907d","permalink":"/talk/cumc_derm_lecture_keratinocyte_biology-01-28-15/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_keratinocyte_biology-01-28-15/","section":"talk","summary":"","tags":["Education","Dermatology"],"title":"Biology of Keratinocytes","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1397642400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1397642400,"objectID":"0bbce8ca689efea3cd2d963180c4ea0f","permalink":"/talk/cumc_derm_grand_rounds-04-16-2014/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-04-16-2014/","section":"talk","summary":"","tags":["Melanoma","Education","Columbia University Medical Center","Dermatology","Medical Oncology"],"title":"Emerging Therapies in Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1394031600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1394031600,"objectID":"5a2bddaeb34cffe525da0a54f25f7f3e","permalink":"/talk/cumc_derm_book_club_environment-03-05-14/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_environment-03-05-14/","section":"talk","summary":"","tags":["Dermatology","Education"],"title":"Environmental and Sports-Related Skin Diseases","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1392804000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1392804000,"objectID":"7d89f0aef927915f08940632af7c3409","permalink":"/talk/cumc_derm_grand_rounds-02-19-2014/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-02-19-2014/","section":"talk","summary":"","tags":["Macrophage Activating Syndrome","Education","Columbia University Medical Center","Dermatology","HLH","Hemophagocytic Lymhpohistiocytosis"],"title":"Overstimulated","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1388934000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1388934000,"objectID":"dc1f8130d93c145b8aa358dc92f248ac","permalink":"/talk/cumc_derm_lecture_t-cell_immunity-01-08-14/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_t-cell_immunity-01-08-14/","section":"talk","summary":"","tags":["Education","Dermatology","Immunology"],"title":"Immunology Review - T-Cell Immunity","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1369227600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1369227600,"objectID":"c24cd3ac0ac6b3dd5326628668823782","permalink":"/talk/cumc_derm_grand_rounds-nfd-05-22-2013/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-nfd-05-22-2013/","section":"talk","summary":"","tags":["Education","Columbia University Medical Center","Dermatology","Nephrogenic Systemic Fibrosis"],"title":"Progression After Failure","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1369220400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1369220400,"objectID":"dd4a9aa77f3babea8a6960c30be7a328","permalink":"/talk/cumc_derm_grand_rounds-scabie-05-22-2013/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-scabie-05-22-2013/","section":"talk","summary":"","tags":["Education","Columbia University Medical Center","Dermatology","Scabies"],"title":"Deep Impact","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1366988400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1366988400,"objectID":"5a8f155f9f7ee59d0c9f79258ae53f7c","permalink":"/talk/cumc_derm_book_club_melanoma-04-26-13/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_melanoma-04-26-13/","section":"talk","summary":"","tags":["Dermatology","Education","Melanoma"],"title":"Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1363791600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1363791600,"objectID":"fba1cfcdb3cdb47b131daba69c0dc17a","permalink":"/talk/cumc_derm_book_club_environment-03-20-13/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_environment-03-20-13/","section":"talk","summary":"","tags":["Dermatology","Education"],"title":"Environmental and Sports-Related Skin Diseases","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1345647600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1345647600,"objectID":"93961e6ec904d4b7661d7eb7acdf21e4","permalink":"/talk/cumc_derm_lecture_b-cell_immunity-08-22-12/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_b-cell_immunity-08-22-12/","section":"talk","summary":"","tags":["Education","Dermatology","Immunology"],"title":"B-Cell Immunology for the Dermatologist","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1345042800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1345042800,"objectID":"8bd402ca3321f4213d4d82f43db60653","permalink":"/talk/cumc_derm_lecture_t-cell_immunity-08-15-12/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_lecture_t-cell_immunity-08-15-12/","section":"talk","summary":"","tags":["Education","Dermatology","Immunology"],"title":"T-Cell Immunology for the Dermatologist","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1344610800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1344610800,"objectID":"217ddf9fce66ffc9e14b76fd684eb12d","permalink":"/talk/cumc_derm_book_club_keratinocytes-08-10-12/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_keratinocytes-08-10-12/","section":"talk","summary":"","tags":["Dermatology","Education","Keratinocytes"],"title":"Biology of Keratinocytes","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1337180400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1337180400,"objectID":"d9a2c23bee3aedef57a07a3d4f8cddaa","permalink":"/talk/cumc_derm_grand_rounds-scc-05-16-2012/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-scc-05-16-2012/","section":"talk","summary":"","tags":["Education","Columbia University Medical Center","Dermatology","Squamous Cell Carcinoma"],"title":"Severe Scalp SCCs In a Heart Transplant Recipient","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1335366000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1335366000,"objectID":"ffd5981c239c0dc971263c1cf2e1e805","permalink":"/talk/cumc_derm_book_club_b-cell-lymphoma-04-25-12/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_b-cell-lymphoma-04-25-12/","section":"talk","summary":"","tags":["Cutaneous B-Cell Lymphoma","Dermatology","Education"],"title":"Cutaneous B-Cell Lymphoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1334329200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1334329200,"objectID":"2ed5fb8f9ca860ed855cd611f4ee8f49","permalink":"/talk/cumc_derm_book_club_melanoma-04-13-12/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_book_club_melanoma-04-13-12/","section":"talk","summary":"","tags":["Dermatology","Education","Melanoma"],"title":"Melanoma","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":"","date":1327485600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1327485600,"objectID":"31b02709c21a895014464a4ea4850e33","permalink":"/talk/cumc_derm_grand_rounds-reed-01-25-2012/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/talk/cumc_derm_grand_rounds-reed-01-25-2012/","section":"talk","summary":"","tags":["Education","Columbia University Medical Center","Dermatology","Reed Syndrome"],"title":"Painful Papules","type":"talk"},{"authors":["David Michael Miller"],"categories":null,"content":" Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.\n","date":1270080000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1270080000,"objectID":"dee6af384c0df8187fba8ea9e5487dbf","permalink":"/publication/parameters-for-establishing-humanized-mouse-models/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/parameters-for-establishing-humanized-mouse-models/","section":"publication","summary":"Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.","tags":[],"title":"Parameters for Establishing Humanized Mouse Models","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance.\n","date":1228089600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1228089600,"objectID":"02d59b32facaa9f53a8a22f97c74573e","permalink":"/publication/tlr-agonists-abrogate-mixed-chimerism/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/tlr-agonists-abrogate-mixed-chimerism/","section":"publication","summary":"TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance.","tags":[],"title":"TLR Activation Abrogates Mixed Chimerism","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" Viral infection: a potent barrier to transplantation tolerance.\n","date":1214438400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1214438400,"objectID":"fa72f731ad9d66d2e4559d2fa7bc766e","permalink":"/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/","section":"publication","summary":"Viral infection: a potent barrier to transplantation tolerance.","tags":[],"title":"Viral infection - a potent barrier to transplantation tolerance","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.\n","date":1209600000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1209600000,"objectID":"41314c327b610d1a201e4784dbf55da6","permalink":"/publication/tlr-agonists-abrogate-immune-tolerance/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/tlr-agonists-abrogate-immune-tolerance/","section":"publication","summary":"TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.","tags":[],"title":"TLR Agonists Abrogate Immunological Tolerance","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" Role of Innate Immunity in Transplantation Tolerance.\n","date":1207008000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1207008000,"objectID":"ea00cf4f0bede5d11973f4bafd88f7f1","permalink":"/publication/role-of-innate-immunity-in-transplantation-tolerance/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/role-of-innate-immunity-in-transplantation-tolerance/","section":"publication","summary":"Role of Innate Immunity in Transplantation Tolerance.","tags":[],"title":"Role of Innate Immunity in Transplantation Tolerance","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice.\n","date":1181347200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1181347200,"objectID":"8b5973ab847d3ff91b11dfdb0deeafce","permalink":"/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/","section":"publication","summary":"Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice.","tags":[],"title":"Different mechanisms control peripheral and central tolerance","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":"Overview The objective of this research was to investigate the ability of mesenchymal stem cells (MSCs), isolated from human bone marrow and human umbilical cord blood, to be used as cellular therapy for diabetes mellitus\n","date":1120210200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1120210200,"objectID":"42011dc92e94f13bf274f4d9bee0f51f","permalink":"/funding/ada-fellowship/","publishdate":"2019-11-24T18:00:00Z","relpermalink":"/funding/ada-fellowship/","section":"funding","summary":"Umbilical cord blood stem cells as therapy for Diabetes Mellitus","tags":null,"title":"American Diabetes Association Physician Scientist Training Award","type":"funding"},{"authors":["David Michael Miller"],"categories":null,"content":" Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin.\n","date":1095724800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1095724800,"objectID":"fa41013d57deb5a3430c39a89948ba8c","permalink":"/publication/jellypin/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/jellypin/","section":"publication","summary":"Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin.","tags":[],"title":"Jellypin -  a lower eukaryotic serine proteinase inhibitor (serpin)","type":"publication"},{"authors":["David Michael Miller"],"categories":null,"content":" The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases.\n","date":1015286400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1015286400,"objectID":"ed4a92721a08cd9e635ad84478cc3920","permalink":"/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/","publishdate":"2019-12-06T00:00:00Z","relpermalink":"/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/","section":"publication","summary":"The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases.","tags":[],"title":"The Serpin SQN-5","type":"publication"},{"authors":["David Michael Miller","Sophia Shalhout"],"categories":null,"content":"       Overview  This is an RMarkdown explaining how we use the Plotly package to more effectivley communicate clinical and translational research via interactive graphs Plotly is a computing company that develops online data analytics and visualization tools It has open sourced many useful interactive visualization products. Plotly can be used in several programming languages (e.g. Python, R and JavaScript)  This tutorial will be written with instruction for R users Although https://plot.ly/ is fabulous resource, we found that there were elements from those tutorials that were missing and we hope that this post will provide a useful resource to get started in Plotly in R  Why use Plotly?  Plotly allows us to create visually appealing interactive plots. The ability to export to html and retain all interactive functionality is easily accomplished with Plotly. It is focused around the ability to generate interactive plots with a few lines of code. Finally, all interactive features are compatible with modern web browsers.    Step 1, Download Plotly from CRAN  Use the install.package() function to install the plotly R package from CRAN install.packages(\u0026quot;plotly\u0026quot;)   Load Relevant Packages library(tidyverse) library(knitr) library(plotly) library(readxl) library(scales)  Load dataset  For the first example we will use mtcars (Motor Trend Car Road Tests), which is built into base R  mtcars \u0026lt;- mtcars View the mtcars Data Frame mtcars %\u0026gt;% kable    mpg cyl disp hp drat wt qsec vs am gear carb    Mazda RX4 21.0 6 160.0 110 3.90 2.620 16.46 0 1 4 4  Mazda RX4 Wag 21.0 6 160.0 110 3.90 2.875 17.02 0 1 4 4  Datsun 710 22.8 4 108.0 93 3.85 2.320 18.61 1 1 4 1  Hornet 4 Drive 21.4 6 258.0 110 3.08 3.215 19.44 1 0 3 1  Hornet Sportabout 18.7 8 360.0 175 3.15 3.440 17.02 0 0 3 2  Valiant 18.1 6 225.0 105 2.76 3.460 20.22 1 0 3 1  Duster 360 14.3 8 360.0 245 3.21 3.570 15.84 0 0 3 4  Merc 240D 24.4 4 146.7 62 3.69 3.190 20.00 1 0 4 2  Merc 230 22.8 4 140.8 95 3.92 3.150 22.90 1 0 4 2  Merc 280 19.2 6 167.6 123 3.92 3.440 18.30 1 0 4 4  Merc 280C 17.8 6 167.6 123 3.92 3.440 18.90 1 0 4 4  Merc 450SE 16.4 8 275.8 180 3.07 4.070 17.40 0 0 3 3  Merc 450SL 17.3 8 275.8 180 3.07 3.730 17.60 0 0 3 3  Merc 450SLC 15.2 8 275.8 180 3.07 3.780 18.00 0 0 3 3  Cadillac Fleetwood 10.4 8 472.0 205 2.93 5.250 17.98 0 0 3 4  Lincoln Continental 10.4 8 460.0 215 3.00 5.424 17.82 0 0 3 4  Chrysler Imperial 14.7 8 440.0 230 3.23 5.345 17.42 0 0 3 4  Fiat 128 32.4 4 78.7 66 4.08 2.200 19.47 1 1 4 1  Honda Civic 30.4 4 75.7 52 4.93 1.615 18.52 1 1 4 2  Toyota Corolla 33.9 4 71.1 65 4.22 1.835 19.90 1 1 4 1  Toyota Corona 21.5 4 120.1 97 3.70 2.465 20.01 1 0 3 1  Dodge Challenger 15.5 8 318.0 150 2.76 3.520 16.87 0 0 3 2  AMC Javelin 15.2 8 304.0 150 3.15 3.435 17.30 0 0 3 2  Camaro Z28 13.3 8 350.0 245 3.73 3.840 15.41 0 0 3 4  Pontiac Firebird 19.2 8 400.0 175 3.08 3.845 17.05 0 0 3 2  Fiat X1-9 27.3 4 79.0 66 4.08 1.935 18.90 1 1 4 1  Porsche 914-2 26.0 4 120.3 91 4.43 2.140 16.70 0 1 5 2  Lotus Europa 30.4 4 95.1 113 3.77 1.513 16.90 1 1 5 2  Ford Pantera L 15.8 8 351.0 264 4.22 3.170 14.50 0 1 5 4  Ferrari Dino 19.7 6 145.0 175 3.62 2.770 15.50 0 1 5 6  Maserati Bora 15.0 8 301.0 335 3.54 3.570 14.60 0 1 5 8  Volvo 142E 21.4 4 121.0 109 4.11 2.780 18.60 1 1 4 2      Make an Interactive Bar Chart in Plotly  For this first example, we will make a bar chart of the number of vehicles with “4”, “6” and “8” cylinders\n One approach is to create a new data frame with two vectors (columns)  one that we create with the String “Four Cylinders”, “Six Cylinders”, and “Eight Cylinders” and\n another Vector that is the sum of all of the rows in mtcars that have a “4”, “6” or “8” in them. We’ll call the first vector “vehicles” and the second “cylinders”\n  This allows us to make a table that has a very defined x-axis and y-axis to make construtcting a bar graph very straight forward  vehicles \u0026lt;- c(\u0026quot;Four Cylinders\u0026quot;,\u0026quot;Six Cylinders\u0026quot;,\u0026quot;Eight Cylinders\u0026quot;) cylinders \u0026lt;- c(sum(mtcars$cyl==4), sum(mtcars$cyl==6), sum(mtcars$cyl==8)) # of note, the sum() function will allow us to add up all the observations with either a \u0026quot;4\u0026quot; or a \u0026quot;6\u0026quot; or a \u0026quot;8\u0026quot;  View these two vectors vehicles %\u0026gt;% kable   x    Four Cylinders  Six Cylinders  Eight Cylinders    cylinders %\u0026gt;% kable   x    11  7  14     As you can see, there are 11 vehicles with “4” contained in the columns’ cells, 7 with “6” and 14 with “8”\n Now combine these two vectors into a tibble, we’ll call it “veh_cyl”  Of note, a tibble is a modern rework of the standard data.frame, with some internal improvements to make code more reliable.  They are data frames, but do not follow all of the same rules  For example, tibbles can have column names that are not normally allowed, such as numbers/symbols.     veh_cyl \u0026lt;- tibble(vehicles, cylinders)   View new Tibble veh_cyl %\u0026gt;% kable   vehicles cylinders    Four Cylinders 11  Six Cylinders 7  Eight Cylinders 14    Now that we have a tibble that can be easily turned into a bar graph, let’s use Plotly to make an interactive graph plot_ly(data = veh_cyl, x = vehicles, y = cylinders, type = \u0026quot;bar\u0026quot;, text = cylinders, textposition = \u0026quot;auto\u0026quot;) %\u0026gt;% layout(title = \u0026quot;Number of Vehicles in mtcars with 4, 6, and 8 Cylinders\u0026quot;, titlefont = list(size = 28, color = \u0026quot;orange\u0026quot;, family = \u0026quot;Calibri\u0026quot;), yaxis = list(title = \u0026quot;Number of Vehicles\u0026quot;, titlefont = list(color = \u0026quot;black\u0026quot;, family = \u0026quot;Arial\u0026quot;, size = 26), tickfont = list(color = \u0026quot;black\u0026quot;, family = \u0026quot;Arial\u0026quot;, size = 20)), xaxis = list(title = \u0026quot;Number of Cylinders\u0026quot;, titlefont = list(color = \u0026quot;red\u0026quot;, family = \u0026quot;Times New Roman\u0026quot;, size = 22), tickfont = list(color = \u0026quot;green\u0026quot;, family = \u0026quot;Cambria\u0026quot;, size = 18)))%\u0026gt;% layout(margin = list( l = 10, r = 10, b = 0, t = 40)) # Use the layout(margin) function to adjust the margins of the graph ## Warning: The titlefont attribute is deprecated. Use title = list(font = ...) ## instead.  {\"x\":{\"visdat\":{\"75e9611e0c34\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75e9611e0c34\",\"attrs\":{\"75e9611e0c34\":{\"x\":[\"Four Cylinders\",\"Six Cylinders\",\"Eight Cylinders\"],\"y\":[11,7,14],\"text\":[11,7,14],\"textposition\":\"auto\",\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"bar\"}},\"layout\":{\"margin\":{\"b\":0,\"l\":10,\"t\":40,\"r\":10},\"title\":\"Number of Vehicles in mtcars with 4, 6, and 8 Cylinders\",\"titlefont\":{\"size\":28,\"color\":\"orange\",\"family\":\"Calibri\"},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Number of Vehicles\",\"titlefont\":{\"color\":\"black\",\"family\":\"Arial\",\"size\":26},\"tickfont\":{\"color\":\"black\",\"family\":\"Arial\",\"size\":20}},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Number of Cylinders\",\"titlefont\":{\"color\":\"red\",\"family\":\"Times New Roman\",\"size\":22},\"tickfont\":{\"color\":\"green\",\"family\":\"Cambria\",\"size\":18},\"type\":\"category\",\"categoryorder\":\"array\",\"categoryarray\":[\"Eight Cylinders\",\"Four Cylinders\",\"Six Cylinders\"]},\"hovermode\":\"closest\",\"showlegend\":false},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[\"Four Cylinders\",\"Six Cylinders\",\"Eight Cylinders\"],\"y\":[11,7,14],\"text\":[11,7,14],\"textposition\":[\"auto\",\"auto\",\"auto\"],\"type\":\"bar\",\"marker\":{\"color\":\"rgba(31,119,180,1)\",\"line\":{\"color\":\"rgba(31,119,180,1)\"}},\"error_y\":{\"color\":\"rgba(31,119,180,1)\"},\"error_x\":{\"color\":\"rgba(31,119,180,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}  Comments about code for Titles and Axes  To adjust the title, axes and margins, plotly uses different code that perhaps the more popular ggpolot package that R users are often very familiar with  The layout() and list() functions perform much of the work for these tasks, as seen above In order to highlight how these are used, we’ve made the title Orange and the axis font Green and the axis title Red to emphaise those elements of the code.\n  To add the values of the bar on the top of the bars use textposition = \u0026quot;auto\u0026quot; in the first ()\n You don’t have to use those codes to adjust your Titles and Axes, but if you don’t a very basic plot will look like this…  plot_ly(data = veh_cyl, x = vehicles, y = cylinders, type = \u0026quot;bar\u0026quot;, text = cylinders)  {\"x\":{\"visdat\":{\"75e93c4b916f\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75e93c4b916f\",\"attrs\":{\"75e93c4b916f\":{\"x\":[\"Four Cylinders\",\"Six Cylinders\",\"Eight Cylinders\"],\"y\":[11,7,14],\"text\":[11,7,14],\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"bar\"}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":[],\"type\":\"category\",\"categoryorder\":\"array\",\"categoryarray\":[\"Eight Cylinders\",\"Four Cylinders\",\"Six Cylinders\"]},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":[]},\"hovermode\":\"closest\",\"showlegend\":false},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[\"Four Cylinders\",\"Six Cylinders\",\"Eight Cylinders\"],\"y\":[11,7,14],\"text\":[11,7,14],\"type\":\"bar\",\"marker\":{\"color\":\"rgba(31,119,180,1)\",\"line\":{\"color\":\"rgba(31,119,180,1)\"}},\"error_y\":{\"color\":\"rgba(31,119,180,1)\"},\"error_x\":{\"color\":\"rgba(31,119,180,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}   Make a Time Series in Plolty  We will use a data set downloaded from GitHub that has dates and corresponding data This will also highlight how to download data directly from GitHub into your R Studio you will need the packages httr and RCurl  library(httr) library(RCurl) Download List of publications from Github  We are going to uses a dataset from Reproducible Research in Ecology, Evolution, Behaviour, and Environmental Studies https://github.com/opetchey/RREEBES/tree/master/Beninca_etal_2008_Nature  no2 \u0026lt;- read.csv(text=getURL(\u0026quot;https://raw.githubusercontent.com/opetchey/RREEBES/master/Beninca_etal_2008_Nature/data/nutrients_original.csv\u0026quot;), skip=7, header=T)  Convert first column into dates no2$Date \u0026lt;- as.Date(no2$Date, \u0026quot;%d/%m/%y\u0026quot;) # of note, this %d/%m/%y format is critical, and is specific to the way the data is put into the data frame; b/c here the date in the original df is d/m/2 digit year, you need a lower case \u0026quot;y\u0026quot; to indicate that year is only two digits in the data frame  Graph a Timeseries in Plotly plot_ly( data = no2, x = no2$Date, y = no2$NO2) %\u0026gt;% add_trace(type = \u0026quot;scatter\u0026quot; ,mode = \u0026quot;lines+markers\u0026quot;) %\u0026gt;% layout( title = \u0026quot;Time Series of NO2\u0026quot;, xaxis = list( title = \u0026quot;Year\u0026quot;), yaxis = list( title = \u0026quot;NO2\u0026quot;))  {\"x\":{\"visdat\":{\"75e915b4c400\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75e915b4c400\",\"attrs\":{\"75e915b4c400\":{\"x\":[\"1990-09-18\",\"1990-09-24\",\"1990-10-01\",\"1990-10-09\",\"1990-10-15\",\"1990-10-22\",\"1990-10-29\",\"1990-11-05\",\"1990-11-12\",\"1990-11-19\",\"1990-11-26\",\"1990-12-03\",\"1990-12-10\",\"1990-12-17\",\"1990-12-24\",\"1990-12-31\",\"1991-01-07\",\"1991-01-14\",\"1991-01-21\",\"1991-01-28\",\"1991-02-04\",\"1991-02-11\",\"1991-02-18\",\"1991-02-25\",\"1991-03-04\",\"1991-03-11\",\"1991-03-18\",\"1991-03-25\",\"1991-04-01\",\"1991-04-08\",\"1991-04-15\",\"1991-04-22\",\"1991-04-29\",\"1991-05-06\",\"1991-05-14\",\"1991-05-21\",\"1991-05-27\",\"1991-06-03\",\"1991-06-10\",\"1991-06-17\",\"1991-06-24\",\"1991-07-08\",\"1991-07-15\",\"1991-07-22\",\"1991-08-05\",\"1991-08-12\",\"1991-08-19\",\"1991-08-26\",\"1991-09-02\",\"1991-09-09\",\"1991-09-16\",\"1991-09-23\",\"1991-09-30\",\"1991-10-07\",\"1991-10-14\",\"1991-10-21\",\"1991-10-28\",\"1991-11-04\",\"1991-11-11\",\"1991-11-18\",\"1991-11-25\",\"1991-12-02\",\"1991-12-09\",\"1991-12-16\",\"1991-12-24\",\"1992-01-06\",\"1992-01-13\",\"1992-01-20\",\"1992-01-27\",\"1992-02-11\",\"1992-02-18\",\"1992-02-27\",\"1992-03-04\",\"1992-03-17\",\"1992-03-24\",\"1992-03-31\",\"1992-04-06\",\"1992-04-13\",\"1992-04-21\",\"1992-04-28\",\"1992-05-05\",\"1992-05-12\",\"1992-05-19\",\"1992-05-26\",\"1992-06-02\",\"1992-06-09\",\"1992-06-15\",\"1992-06-22\",\"1992-06-30\",\"1992-07-14\",\"1992-07-21\",\"1992-07-28\",\"1992-08-04\",\"1992-08-11\",\"1992-08-18\",\"1992-08-25\",\"1992-09-01\",\"1992-09-15\",\"1992-09-18\",\"1992-09-22\",\"1992-09-29\",\"1992-10-07\",\"1992-10-13\",\"1992-10-26\",\"1992-11-02\",\"1992-11-16\",\"1992-11-23\",\"1992-11-30\",\"1992-12-07\",\"1992-12-14\",\"1992-12-21\",\"1992-12-28\",\"1993-01-06\",\"1993-01-11\",\"1993-01-18\",\"1993-01-25\",\"1993-02-01\",\"1993-02-08\",\"1993-02-16\",\"1993-02-22\",\"1993-03-01\",\"1993-03-09\",\"1993-03-15\",\"1993-03-22\",\"1993-03-29\",\"1993-04-05\",\"1993-04-14\",\"1993-04-19\",\"1993-04-26\",\"1993-05-03\",\"1993-05-10\",\"1993-05-27\",\"1993-06-01\",\"1993-06-07\",\"1993-06-17\",\"1993-06-21\",\"1993-06-28\",\"1993-07-05\",\"1993-07-13\",\"1993-07-19\",\"1993-07-26\",\"1993-08-02\",\"1993-08-09\",\"1993-08-16\",\"1993-08-23\",\"1993-08-30\",\"1993-09-06\",\"1993-09-13\",\"1993-09-20\",\"1993-09-27\",\"1993-10-04\",\"1993-10-11\",\"1993-11-01\",\"1993-11-15\",\"1993-11-22\",\"1993-11-29\",\"1993-12-06\",\"1993-12-13\",\"1993-12-20\",\"1994-01-03\",\"1994-01-10\",\"1994-01-17\",\"1994-01-24\",\"1994-01-31\",\"1994-02-07\",\"1994-02-14\",\"1994-02-21\",\"1994-02-28\",\"1994-03-07\",\"1994-03-14\",\"1994-03-21\",\"1994-03-28\",\"1994-04-05\",\"1994-04-11\",\"1994-04-18\",\"1994-04-25\",\"1994-05-02\",\"1994-05-09\",\"1994-05-16\",\"1994-05-24\",\"1994-05-30\",\"1994-06-06\",\"1994-06-13\",\"1994-06-20\",\"1994-06-27\",\"1994-07-04\",\"1994-07-11\",\"1994-07-18\",\"1994-07-25\",\"1994-08-01\",\"1994-08-08\",\"1994-08-15\",\"1994-08-22\",\"1994-08-29\",\"1994-09-06\",\"1994-09-12\",\"1994-09-19\",\"1994-09-26\",\"1994-10-04\",\"1994-10-10\",\"1994-10-17\",\"1994-10-24\",\"1994-11-01\",\"1994-11-07\",\"1994-11-11\",\"1994-11-21\",\"1994-11-28\",\"1994-12-05\",\"1994-12-12\",\"1994-12-19\",\"1995-01-03\",\"1995-01-09\",\"1995-01-16\",\"1995-01-23\",\"1995-01-30\",\"1995-02-06\",\"1995-02-20\",\"1995-02-27\",\"1995-03-06\",\"1995-03-13\",\"1995-03-20\",\"1995-03-27\",\"1995-04-03\",\"1995-04-10\",\"1995-04-18\",\"1995-04-24\",\"1995-05-02\",\"1995-05-08\",\"1995-05-15\",\"1995-05-22\",\"1995-05-29\",\"1995-06-06\",\"1995-06-19\",\"1995-07-04\",\"1995-07-10\",\"1995-07-17\",\"1995-07-24\",\"1995-07-31\",\"1995-08-07\",\"1995-08-14\",\"1995-08-21\",\"1995-08-28\",\"1995-09-04\",\"1995-09-12\",\"1995-09-18\",\"1995-09-25\",\"1995-10-09\",\"1995-10-16\",\"1995-10-23\",\"1995-11-02\",\"1995-11-06\",\"1995-11-13\",\"1995-11-20\",\"1995-11-27\",\"1995-12-05\",\"1995-12-12\",\"1995-12-18\",\"1996-01-02\",\"1996-01-08\",\"1996-01-15\",\"1996-01-22\",\"1996-01-25\",\"1996-02-05\",\"1996-02-12\",\"1996-02-19\",\"1996-02-26\",\"1996-03-05\",\"1996-03-11\",\"1996-03-18\",\"1996-03-25\",\"1996-04-01\",\"1996-04-15\",\"1996-04-22\",\"1996-04-29\",\"1996-05-06\",\"1996-05-13\",\"1996-05-20\",\"1996-05-28\",\"1996-06-03\",\"1996-06-10\",\"1996-06-17\",\"1996-06-24\",\"1996-07-01\",\"1996-07-08\",\"1996-07-15\",\"1996-07-22\",\"1996-07-29\",\"1996-08-05\",\"1996-08-12\",\"1996-08-19\",\"1996-08-26\",\"1996-09-02\",\"1996-09-09\",\"1996-09-16\",\"1996-09-23\",\"1996-09-30\",\"1996-10-07\",\"1996-10-14\",\"1996-10-21\",\"1996-10-28\",\"1996-11-04\",\"1996-11-11\",\"1996-11-18\",\"1996-11-25\",\"1996-12-02\",\"1996-12-04\",\"1996-12-16\",\"1997-01-06\",\"1997-01-13\",\"1997-01-20\",\"1997-01-27\",\"1997-02-03\",\"1997-02-10\",\"1997-02-17\",\"1997-02-24\",\"1997-03-03\",\"1997-03-10\",\"1997-03-17\",\"1997-03-24\",\"1997-04-01\",\"1997-04-07\",\"1997-04-14\",\"1997-04-21\",\"1997-04-28\",\"1997-05-05\",\"1997-05-11\",\"1997-05-26\",\"1997-06-02\",\"1997-06-09\",\"1997-06-16\",\"1997-06-23\",\"1997-06-30\",\"1997-07-07\",\"1997-07-14\",\"1997-07-21\",\"1997-07-28\",\"1997-08-04\",\"1997-08-11\",\"1997-08-18\",\"1997-08-25\",\"1997-09-01\",\"1997-09-08\",\"1997-09-15\",\"1997-09-22\",\"1997-09-29\",\"1997-10-06\",\"1997-10-13\",\"1997-10-20\",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"y\":[25.27,17.59,5.36,5.23,5,1.98,5.3,10.27,4.93,11.43,18.73,5.25,4.45,3.32,7,11,15.39,15.09,6.2,6.34,12.52,15,4.73,14.39,2.39,2.32,2.66,11.8,10.61,15.55,14.07,22.27,29.43,1.98,0.77,0.41,2.98,17.2,15,0.14,0.52,0.14,11.32,4.73,0.5,0.39,1.95,1.3,0.68,0.52,0.69,2.11,0.64,4.39,0.45,4.58,0.61,0.39,0.5,0.32,0.55,0.29,0.38,0.52,1.05,1.62,1.05,0.83,1.65,0.38,0.65,0.39,0.9,0.42,0.26,0.17,0.4,0.8,0.35,0.45,0.4,0.94,0.65,0.37,0.71,0.43,0.14,0.95,0.84,0.78,0.51,0.93,0.76,0.87,1.37,1.93,2.13,2.05,1.55,1.89,0.25,0.37,0.07,0.45,0.59,0.69,0.68,0.41,0.5,0.42,0.37,0.22,0.73,0.35,0.58,0.37,0.32,0.35,0.46,0.42,0.41,0.98,0.64,1.55,0.24,0.84,0.72,0.48,0.51,0.5,null,0.49,0.27,0.29,0.21,0.22,0.25,0.3,0.29,0.16,0.34,0.34,0.18,0.2,1.5,1.68,0.29,0.08,0.26,1.91,0.66,0.26,0.7,0.67,0.42,0.81,0.59,0.41,0.27,0.47,0.23,0.32,0.53,0.17,0.41,0.27,0.34,0.62,0.49,0.54,0.48,0.46,0.83,0.53,0.56,0.57,0.18,0.2,0.52,0.92,1.4,0.32,0.37,0.32,0.27,0.28,0.27,0.26,0.36,0.14,0.34,0.38,0.5,3.77,0.56,0.43,0.59,0.3,0.69,0.45,0.66,0.47,0.39,0.51,0.3,0.18,0.18,0.41,0.23,1.15,1.11,0.91,0.36,4.1,0.77,0.7,0.53,0.87,0.16,0.36,0.11,0.33,0.26,0.21,0.25,0.94,1.28,0.22,0.33,0.54,1.21,0.36,0.78,0.24,0.33,0.38,0.36,0.56,0.41,0.55,0.26,0.45,0.43,0.3,0.15,0.21,0.73,0.46,0.61,0.16,0.39,0.53,0.29,0.41,1.13,0.8,1.56,0.34,0.21,0.06,0.37,0.38,0.22,0.19,1.26,0.14,0.15,0.22,0.19,0.7,0.42,0.51,0.29,0.22,0.3,0.2,0.49,0.55,0.53,1.3,3.15,2.86,0.2,4.41,10.33,9.82,10.24,44.32,0.57,0.57,1.52,0.34,0.41,0.33,0.21,0.88,1.92,25.02,1.4,0.47,0.51,0.29,6.32,8.87,16.17,13.9,45.9,1.11,0.5,0.9,1.26,1.78,0.83,1.2,0.59,0.07,0.18,0.21,2.09,0.18,0.49,0.24,0.11,0.19,0.17,0.23,0.22,0.08,0.22,0.11,0.08,0.04,0.26,0.07,0.14,0.13,0.11,0.39,2.97,0.11,0.05,0.16,0.07,0.11,0.14,0.15,0.09,0.15,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"inherit\":true}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Time Series of NO2\",\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Year\"},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"NO2\"},\"hovermode\":\"closest\",\"showlegend\":false},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[\"1990-09-18\",\"1990-09-24\",\"1990-10-01\",\"1990-10-09\",\"1990-10-15\",\"1990-10-22\",\"1990-10-29\",\"1990-11-05\",\"1990-11-12\",\"1990-11-19\",\"1990-11-26\",\"1990-12-03\",\"1990-12-10\",\"1990-12-17\",\"1990-12-24\",\"1990-12-31\",\"1991-01-07\",\"1991-01-14\",\"1991-01-21\",\"1991-01-28\",\"1991-02-04\",\"1991-02-11\",\"1991-02-18\",\"1991-02-25\",\"1991-03-04\",\"1991-03-11\",\"1991-03-18\",\"1991-03-25\",\"1991-04-01\",\"1991-04-08\",\"1991-04-15\",\"1991-04-22\",\"1991-04-29\",\"1991-05-06\",\"1991-05-14\",\"1991-05-21\",\"1991-05-27\",\"1991-06-03\",\"1991-06-10\",\"1991-06-17\",\"1991-06-24\",\"1991-07-08\",\"1991-07-15\",\"1991-07-22\",\"1991-08-05\",\"1991-08-12\",\"1991-08-19\",\"1991-08-26\",\"1991-09-02\",\"1991-09-09\",\"1991-09-16\",\"1991-09-23\",\"1991-09-30\",\"1991-10-07\",\"1991-10-14\",\"1991-10-21\",\"1991-10-28\",\"1991-11-04\",\"1991-11-11\",\"1991-11-18\",\"1991-11-25\",\"1991-12-02\",\"1991-12-09\",\"1991-12-16\",\"1991-12-24\",\"1992-01-06\",\"1992-01-13\",\"1992-01-20\",\"1992-01-27\",\"1992-02-11\",\"1992-02-18\",\"1992-02-27\",\"1992-03-04\",\"1992-03-17\",\"1992-03-24\",\"1992-03-31\",\"1992-04-06\",\"1992-04-13\",\"1992-04-21\",\"1992-04-28\",\"1992-05-05\",\"1992-05-12\",\"1992-05-19\",\"1992-05-26\",\"1992-06-02\",\"1992-06-09\",\"1992-06-15\",\"1992-06-22\",\"1992-06-30\",\"1992-07-14\",\"1992-07-21\",\"1992-07-28\",\"1992-08-04\",\"1992-08-11\",\"1992-08-18\",\"1992-08-25\",\"1992-09-01\",\"1992-09-15\",\"1992-09-18\",\"1992-09-22\",\"1992-09-29\",\"1992-10-07\",\"1992-10-13\",\"1992-10-26\",\"1992-11-02\",\"1992-11-16\",\"1992-11-23\",\"1992-11-30\",\"1992-12-07\",\"1992-12-14\",\"1992-12-21\",\"1992-12-28\",\"1993-01-06\",\"1993-01-11\",\"1993-01-18\",\"1993-01-25\",\"1993-02-01\",\"1993-02-08\",\"1993-02-16\",\"1993-02-22\",\"1993-03-01\",\"1993-03-09\",\"1993-03-15\",\"1993-03-22\",\"1993-03-29\",\"1993-04-05\",\"1993-04-14\",\"1993-04-19\",\"1993-04-26\",\"1993-05-03\",null,\"1993-05-27\",\"1993-06-01\",\"1993-06-07\",\"1993-06-17\",\"1993-06-21\",\"1993-06-28\",\"1993-07-05\",\"1993-07-13\",\"1993-07-19\",\"1993-07-26\",\"1993-08-02\",\"1993-08-09\",\"1993-08-16\",\"1993-08-23\",\"1993-08-30\",\"1993-09-06\",\"1993-09-13\",\"1993-09-20\",\"1993-09-27\",\"1993-10-04\",\"1993-10-11\",\"1993-11-01\",\"1993-11-15\",\"1993-11-22\",\"1993-11-29\",\"1993-12-06\",\"1993-12-13\",\"1993-12-20\",\"1994-01-03\",\"1994-01-10\",\"1994-01-17\",\"1994-01-24\",\"1994-01-31\",\"1994-02-07\",\"1994-02-14\",\"1994-02-21\",\"1994-02-28\",\"1994-03-07\",\"1994-03-14\",\"1994-03-21\",\"1994-03-28\",\"1994-04-05\",\"1994-04-11\",\"1994-04-18\",\"1994-04-25\",\"1994-05-02\",\"1994-05-09\",\"1994-05-16\",\"1994-05-24\",\"1994-05-30\",\"1994-06-06\",\"1994-06-13\",\"1994-06-20\",\"1994-06-27\",\"1994-07-04\",\"1994-07-11\",\"1994-07-18\",\"1994-07-25\",\"1994-08-01\",\"1994-08-08\",\"1994-08-15\",\"1994-08-22\",\"1994-08-29\",\"1994-09-06\",\"1994-09-12\",\"1994-09-19\",\"1994-09-26\",\"1994-10-04\",\"1994-10-10\",\"1994-10-17\",\"1994-10-24\",\"1994-11-01\",\"1994-11-07\",\"1994-11-11\",\"1994-11-21\",\"1994-11-28\",\"1994-12-05\",\"1994-12-12\",\"1994-12-19\",\"1995-01-03\",\"1995-01-09\",\"1995-01-16\",\"1995-01-23\",\"1995-01-30\",\"1995-02-06\",\"1995-02-20\",\"1995-02-27\",\"1995-03-06\",\"1995-03-13\",\"1995-03-20\",\"1995-03-27\",\"1995-04-03\",\"1995-04-10\",\"1995-04-18\",\"1995-04-24\",\"1995-05-02\",\"1995-05-08\",\"1995-05-15\",\"1995-05-22\",\"1995-05-29\",\"1995-06-06\",\"1995-06-19\",\"1995-07-04\",\"1995-07-10\",\"1995-07-17\",\"1995-07-24\",\"1995-07-31\",\"1995-08-07\",\"1995-08-14\",\"1995-08-21\",\"1995-08-28\",\"1995-09-04\",\"1995-09-12\",\"1995-09-18\",\"1995-09-25\",\"1995-10-09\",\"1995-10-16\",\"1995-10-23\",\"1995-11-02\",\"1995-11-06\",\"1995-11-13\",\"1995-11-20\",\"1995-11-27\",\"1995-12-05\",\"1995-12-12\",\"1995-12-18\",\"1996-01-02\",\"1996-01-08\",\"1996-01-15\",\"1996-01-22\",\"1996-01-25\",\"1996-02-05\",\"1996-02-12\",\"1996-02-19\",\"1996-02-26\",\"1996-03-05\",\"1996-03-11\",\"1996-03-18\",\"1996-03-25\",\"1996-04-01\",\"1996-04-15\",\"1996-04-22\",\"1996-04-29\",\"1996-05-06\",\"1996-05-13\",\"1996-05-20\",\"1996-05-28\",\"1996-06-03\",\"1996-06-10\",\"1996-06-17\",\"1996-06-24\",\"1996-07-01\",\"1996-07-08\",\"1996-07-15\",\"1996-07-22\",\"1996-07-29\",\"1996-08-05\",\"1996-08-12\",\"1996-08-19\",\"1996-08-26\",\"1996-09-02\",\"1996-09-09\",\"1996-09-16\",\"1996-09-23\",\"1996-09-30\",\"1996-10-07\",\"1996-10-14\",\"1996-10-21\",\"1996-10-28\",\"1996-11-04\",\"1996-11-11\",\"1996-11-18\",\"1996-11-25\",\"1996-12-02\",\"1996-12-04\",\"1996-12-16\",\"1997-01-06\",\"1997-01-13\",\"1997-01-20\",\"1997-01-27\",\"1997-02-03\",\"1997-02-10\",\"1997-02-17\",\"1997-02-24\",\"1997-03-03\",\"1997-03-10\",\"1997-03-17\",\"1997-03-24\",\"1997-04-01\",\"1997-04-07\",\"1997-04-14\",\"1997-04-21\",\"1997-04-28\",\"1997-05-05\",\"1997-05-11\",\"1997-05-26\",\"1997-06-02\",\"1997-06-09\",\"1997-06-16\",\"1997-06-23\",\"1997-06-30\",\"1997-07-07\",\"1997-07-14\",\"1997-07-21\",\"1997-07-28\",\"1997-08-04\",\"1997-08-11\",\"1997-08-18\",\"1997-08-25\",\"1997-09-01\",\"1997-09-08\",\"1997-09-15\",\"1997-09-22\",\"1997-09-29\",\"1997-10-06\",\"1997-10-13\",\"1997-10-20\"],\"y\":[25.27,17.59,5.36,5.23,5,1.98,5.3,10.27,4.93,11.43,18.73,5.25,4.45,3.32,7,11,15.39,15.09,6.2,6.34,12.52,15,4.73,14.39,2.39,2.32,2.66,11.8,10.61,15.55,14.07,22.27,29.43,1.98,0.77,0.41,2.98,17.2,15,0.14,0.52,0.14,11.32,4.73,0.5,0.39,1.95,1.3,0.68,0.52,0.69,2.11,0.64,4.39,0.45,4.58,0.61,0.39,0.5,0.32,0.55,0.29,0.38,0.52,1.05,1.62,1.05,0.83,1.65,0.38,0.65,0.39,0.9,0.42,0.26,0.17,0.4,0.8,0.35,0.45,0.4,0.94,0.65,0.37,0.71,0.43,0.14,0.95,0.84,0.78,0.51,0.93,0.76,0.87,1.37,1.93,2.13,2.05,1.55,1.89,0.25,0.37,0.07,0.45,0.59,0.69,0.68,0.41,0.5,0.42,0.37,0.22,0.73,0.35,0.58,0.37,0.32,0.35,0.46,0.42,0.41,0.98,0.64,1.55,0.24,0.84,0.72,0.48,0.51,0.5,null,0.49,0.27,0.29,0.21,0.22,0.25,0.3,0.29,0.16,0.34,0.34,0.18,0.2,1.5,1.68,0.29,0.08,0.26,1.91,0.66,0.26,0.7,0.67,0.42,0.81,0.59,0.41,0.27,0.47,0.23,0.32,0.53,0.17,0.41,0.27,0.34,0.62,0.49,0.54,0.48,0.46,0.83,0.53,0.56,0.57,0.18,0.2,0.52,0.92,1.4,0.32,0.37,0.32,0.27,0.28,0.27,0.26,0.36,0.14,0.34,0.38,0.5,3.77,0.56,0.43,0.59,0.3,0.69,0.45,0.66,0.47,0.39,0.51,0.3,0.18,0.18,0.41,0.23,1.15,1.11,0.91,0.36,4.1,0.77,0.7,0.53,0.87,0.16,0.36,0.11,0.33,0.26,0.21,0.25,0.94,1.28,0.22,0.33,0.54,1.21,0.36,0.78,0.24,0.33,0.38,0.36,0.56,0.41,0.55,0.26,0.45,0.43,0.3,0.15,0.21,0.73,0.46,0.61,0.16,0.39,0.53,0.29,0.41,1.13,0.8,1.56,0.34,0.21,0.06,0.37,0.38,0.22,0.19,1.26,0.14,0.15,0.22,0.19,0.7,0.42,0.51,0.29,0.22,0.3,0.2,0.49,0.55,0.53,1.3,3.15,2.86,0.2,4.41,10.33,9.82,10.24,44.32,0.57,0.57,1.52,0.34,0.41,0.33,0.21,0.88,1.92,25.02,1.4,0.47,0.51,0.29,6.32,8.87,16.17,13.9,45.9,1.11,0.5,0.9,1.26,1.78,0.83,1.2,0.59,0.07,0.18,0.21,2.09,0.18,0.49,0.24,0.11,0.19,0.17,0.23,0.22,0.08,0.22,0.11,0.08,0.04,0.26,0.07,0.14,0.13,0.11,0.39,2.97,0.11,0.05,0.16,0.07,0.11,0.14,0.15,0.09,0.15],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"marker\":{\"color\":\"rgba(31,119,180,1)\",\"line\":{\"color\":\"rgba(31,119,180,1)\"}},\"error_y\":{\"color\":\"rgba(31,119,180,1)\"},\"error_x\":{\"color\":\"rgba(31,119,180,1)\"},\"line\":{\"color\":\"rgba(31,119,180,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}   Make a Chloropleth Map in Plotly  A Chloropleth Map is a map that uses differences in shading, coloring, or the placing of symbols within predefined areas to indicate the average values of a property or quantity in those areas (https://en.wikipedia.org/wiki/Choropleth_map) For example let’s look at the rate of new cancers in the US according to the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), 2016 Visit “https://gis.cdc.gov/Cancer/USCS/DataViz.html” and click “export” to download a csv file.  Make sure to save it in your project folder Also, please create a column,”state”, and enter the state abbreviations next to the corresponding full state name in “Area”.  This is needed to add values to each state    df \u0026lt;- read.csv(\u0026quot;USCS_OverviewMap.csv\u0026quot;) View the Data Fram df df %\u0026gt;% kable   Code Area CancerType Year Sex AgeAdjustedRate CaseCount Population X    NM ‘New Mexico’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 359.4 9075 2085432 0.0043516  AZ ‘Arizona’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 376.3 31443 6908642 0.0045513  CA ‘California’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 385.6 164887 39296476 0.0041960  CO ‘Colorado’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 388.8 23244 5530105 0.0042032  DC ‘District of Columbia’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 378.3 2566 684336 0.0037496  NV ‘Nevada’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 385.0 13054 2939254 0.0044413  AK ‘Alaska’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 405.8 2882 741522 0.0038866  HI ‘Hawaii’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 414.2 7395 1428683 0.0051761  MA ‘Massachusetts’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 404.2 33626 6823721 0.0049278  OR ‘Oregon’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 405.3 20596 4085989 0.0050406  TX ‘Texas’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 391.8 109083 27904862 0.0039091  UT ‘Utah’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 390.6 10494 3044321 0.0034471  VA ‘Virginia’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 413.3 40322 8414380 0.0047920  WY ‘Wyoming’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 402.3 2775 584910 0.0047443  FL ‘Florida’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 419.3 119408 20656589 0.0057806  ID ‘Idaho’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 439.2 8354 1680026 0.0049725  IN ‘Indiana’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 443.0 34260 6634007 0.0051643  MD ‘Maryland’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 440.9 30942 6024752 0.0051358  MI ‘Michigan’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 436.8 53911 9933445 0.0054272  MN ‘Minnesota’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 455.7 29619 5525050 0.0053609  MO ‘Missouri’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 446.3 33171 6091176 0.0054457  NE ‘Nebraska’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 446.4 9838 1907603 0.0051573  ND ‘North Dakota’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 448.7 3765 755548 0.0049831  OK ‘Oklahoma’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 447.9 20167 3921207 0.0051431  RI ‘Rhode Island’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 450.6 5972 1057566 0.0056469  SC ‘South Carolina’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 440.9 27313 4959822 0.0055069  SD ‘South Dakota’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 449.5 4612 861542 0.0053532  TN ‘Tennessee’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 455.7 36598 6649404 0.0055040  VT ‘Vermont’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 442.4 3681 623354 0.0059052  WA ‘Washington’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 445.1 37378 7280934 0.0051337  AL ‘Alabama’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 457.8 27195 4860545 0.0055951  AR ‘Arkansas’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 469.6 17053 2988231 0.0057067  CT ‘Connecticut’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 465.5 21117 3587685 0.0058860  DE ‘Delaware’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 487.2 6001 952698 0.0062990  GA ‘Georgia’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 468.8 52056 10313620 0.0050473  IL ‘Illinois’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 462.8 68954 12835726 0.0053720  IA ‘Iowa’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 473.6 18146 3130869 0.0057958  KS ‘Kansas’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 457.3 15312 2907731 0.0052660  KY ‘Kentucky’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 509.7 27137 4436113 0.0061173  LA ‘Louisiana’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 473.1 25451 4686157 0.0054311  ME ‘Maine’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 473.4 8901 1330232 0.0066913  MS ‘Mississippi’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 465.8 16265 2985415 0.0054482  MT ‘Montana’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 456.6 6194 1038656 0.0059635  NH ‘New Hampshire’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 480.9 8442 1335015 0.0063235  NJ ‘New Jersey’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 474.8 51521 8978416 0.0057383  NY ‘New York’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 474.8 113026 19836286 0.0056979  NC ‘North Carolina’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 458.4 55394 10156689 0.0054539  OH ‘Ohio’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 456.1 65645 11622554 0.0056481  PA ‘Pennsylvania’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 482.5 80089 12787085 0.0062633  WV ‘West Virginia’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 472.0 11698 1828637 0.0063971  WI ‘Wisconsin’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 458.6 32688 5772917 0.0056623     Add a vector to the Data Frame specifying what will be revealed via hovering df$hover \u0026lt;- with(df, paste(df$Area, df$Year,\u0026quot;Sex:\u0026quot;, df$Sex, \u0026quot;Case count:\u0026quot;, df$CaseCount, sep = \u0026quot;\u0026lt;br\u0026gt;\u0026quot;))  This is a very nice option.  You can create a vector (here we are calling it “hover”) that will be the contents displayed when you hover over the map  This “hover” vector needs to be specified in the text = part of the code below    View the first 2 rows of the data frame df with hover vector kable(head(df[1:2,]))   Code Area CancerType Year Sex AgeAdjustedRate CaseCount Population X hover    NM ‘New Mexico’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 359.4 9075 2085432 0.0043516 ‘New Mexico’\n‘2016’\nSex:\n‘Male and Female’\nCase count:\n9075  AZ ‘Arizona’ ‘All Types of Cancer’ ‘2016’ ‘Male and Female’ 376.3 31443 6908642 0.0045513 ‘Arizona’\n‘2016’\nSex:\n‘Male and Female’\nCase count:\n31443      Plot the Chloropleth Map # give state boundaries a white border l \u0026lt;- list(color = toRGB(\u0026quot;white\u0026quot;), width = 2) # specify some map projection/options g \u0026lt;- list( scope = \u0026#39;usa\u0026#39;, projection = list(type = \u0026#39;albers usa\u0026#39;), showlakes = TRUE, lakecolor = toRGB(\u0026#39;steelblue\u0026#39;) ) p \u0026lt;- plot_geo(df, locationmode = \u0026#39;USA-states\u0026#39;) %\u0026gt;% add_trace( z = ~AgeAdjustedRate, text = ~hover, locations = df$Code, color = ~AgeAdjustedRate, colors = \u0026#39;Purples\u0026#39; ) %\u0026gt;% colorbar(title = \u0026quot;Rate per 100,000 people\u0026quot;) %\u0026gt;% layout( title = \u0026#39;US Cancer Statistics Rate of New Cancers- 2016 (Source: CDC and NCI)\u0026#39;, geo = g ) p  {\"x\":{\"visdat\":{\"75e9e1d473\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75e9e1d473\",\"attrs\":{\"75e9e1d473\":{\"locationmode\":\"USA-states\",\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"z\":{},\"text\":{},\"locations\":[\"NM\",\"AZ\",\"CA\",\"CO\",\"DC\",\"NV\",\"AK\",\"HI\",\"MA\",\"OR\",\"TX\",\"UT\",\"VA\",\"WY\",\"FL\",\"ID\",\"IN\",\"MD\",\"MI\",\"MN\",\"MO\",\"NE\",\"ND\",\"OK\",\"RI\",\"SC\",\"SD\",\"TN\",\"VT\",\"WA\",\"AL\",\"AR\",\"CT\",\"DE\",\"GA\",\"IL\",\"IA\",\"KS\",\"KY\",\"LA\",\"ME\",\"MS\",\"MT\",\"NH\",\"NJ\",\"NY\",\"NC\",\"OH\",\"PA\",\"WV\",\"WI\"],\"color\":{},\"colors\":\"Purples\",\"inherit\":true}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"mapType\":\"geo\",\"scene\":{\"zaxis\":{\"title\":\"AgeAdjustedRate\"}},\"geo\":{\"domain\":{\"x\":[0,1],\"y\":[0,1]},\"scope\":\"usa\",\"projection\":{\"type\":\"albers usa\"},\"showlakes\":true,\"lakecolor\":\"rgba(70,130,180,1)\"},\"hovermode\":\"closest\",\"showlegend\":false,\"legend\":{\"yanchor\":\"top\",\"y\":0.5},\"title\":\"US Cancer Statistics Rate of New Cancers- 2016 (Source: CDC and NCI)\"},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"colorbar\":{\"title\":\"Rate per 100,000 people\",\"ticklen\":2,\"len\":0.5,\"lenmode\":\"fraction\",\"y\":1,\"yanchor\":\"top\"},\"colorscale\":[[\"0\",\"rgba(252,251,253,1)\"],[\"0.0416666666666666\",\"rgba(248,246,250,1)\"],[\"0.0833333333333332\",\"rgba(243,242,248,1)\"],[\"0.125\",\"rgba(239,237,245,1)\"],[\"0.166666666666667\",\"rgba(232,231,242,1)\"],[\"0.208333333333333\",\"rgba(225,224,238,1)\"],[\"0.25\",\"rgba(218,218,235,1)\"],[\"0.291666666666667\",\"rgba(208,208,230,1)\"],[\"0.333333333333333\",\"rgba(198,199,225,1)\"],[\"0.375\",\"rgba(188,189,220,1)\"],[\"0.416666666666667\",\"rgba(178,177,213,1)\"],[\"0.458333333333333\",\"rgba(168,166,207,1)\"],[\"0.5\",\"rgba(158,154,200,1)\"],[\"0.541666666666667\",\"rgba(148,144,195,1)\"],[\"0.583333333333333\",\"rgba(138,135,191,1)\"],[\"0.625\",\"rgba(128,125,186,1)\"],[\"0.666666666666667\",\"rgba(121,110,178,1)\"],[\"0.708333333333333\",\"rgba(114,96,171,1)\"],[\"0.75\",\"rgba(106,81,163,1)\"],[\"0.791666666666667\",\"rgba(99,67,156,1)\"],[\"0.833333333333333\",\"rgba(92,54,150,1)\"],[\"0.875\",\"rgba(84,39,143,1)\"],[\"0.916666666666666\",\"rgba(77,28,137,1)\"],[\"0.958333333333333\",\"rgba(70,16,131,1)\"],[\"1\",\"rgba(63,0,125,1)\"]],\"showscale\":true,\"locationmode\":\"USA-states\",\"z\":[359.4,376.3,385.6,388.8,378.3,385,405.8,414.2,404.2,405.3,391.8,390.6,413.3,402.3,419.3,439.2,443,440.9,436.8,455.7,446.3,446.4,448.7,447.9,450.6,440.9,449.5,455.7,442.4,445.1,457.8,469.6,465.5,487.2,468.8,462.8,473.6,457.3,509.7,473.1,473.4,465.8,456.6,480.9,474.8,474.8,458.4,456.1,482.5,472,458.6],\"text\":[\"'New Mexico'\n'2016'\nSex:\n'Male and Female'\nCase count:\n9075\",\"'Arizona'\n'2016'\nSex:\n'Male and Female'\nCase count:\n31443\",\"'California'\n'2016'\nSex:\n'Male and Female'\nCase count:\n164887\",\"'Colorado'\n'2016'\nSex:\n'Male and Female'\nCase count:\n23244\",\"'District of Columbia'\n'2016'\nSex:\n'Male and Female'\nCase count:\n2566\",\"'Nevada'\n'2016'\nSex:\n'Male and Female'\nCase count:\n13054\",\"'Alaska'\n'2016'\nSex:\n'Male and Female'\nCase count:\n2882\",\"'Hawaii'\n'2016'\nSex:\n'Male and Female'\nCase count:\n7395\",\"'Massachusetts'\n'2016'\nSex:\n'Male and Female'\nCase count:\n33626\",\"'Oregon'\n'2016'\nSex:\n'Male and Female'\nCase count:\n20596\",\"'Texas'\n'2016'\nSex:\n'Male and Female'\nCase count:\n109083\",\"'Utah'\n'2016'\nSex:\n'Male and Female'\nCase count:\n10494\",\"'Virginia'\n'2016'\nSex:\n'Male and Female'\nCase count:\n40322\",\"'Wyoming'\n'2016'\nSex:\n'Male and Female'\nCase count:\n2775\",\"'Florida'\n'2016'\nSex:\n'Male and Female'\nCase count:\n119408\",\"'Idaho'\n'2016'\nSex:\n'Male and Female'\nCase count:\n8354\",\"'Indiana'\n'2016'\nSex:\n'Male and Female'\nCase count:\n34260\",\"'Maryland'\n'2016'\nSex:\n'Male and Female'\nCase count:\n30942\",\"'Michigan'\n'2016'\nSex:\n'Male and Female'\nCase count:\n53911\",\"'Minnesota'\n'2016'\nSex:\n'Male and Female'\nCase count:\n29619\",\"'Missouri'\n'2016'\nSex:\n'Male and Female'\nCase count:\n33171\",\"'Nebraska'\n'2016'\nSex:\n'Male and Female'\nCase count:\n9838\",\"'North Dakota'\n'2016'\nSex:\n'Male and Female'\nCase count:\n3765\",\"'Oklahoma'\n'2016'\nSex:\n'Male and Female'\nCase count:\n20167\",\"'Rhode Island'\n'2016'\nSex:\n'Male and Female'\nCase count:\n5972\",\"'South Carolina'\n'2016'\nSex:\n'Male and Female'\nCase count:\n27313\",\"'South Dakota'\n'2016'\nSex:\n'Male and Female'\nCase count:\n4612\",\"'Tennessee'\n'2016'\nSex:\n'Male and Female'\nCase count:\n36598\",\"'Vermont'\n'2016'\nSex:\n'Male and Female'\nCase count:\n3681\",\"'Washington'\n'2016'\nSex:\n'Male and Female'\nCase count:\n37378\",\"'Alabama'\n'2016'\nSex:\n'Male and Female'\nCase count:\n27195\",\"'Arkansas'\n'2016'\nSex:\n'Male and Female'\nCase count:\n17053\",\"'Connecticut'\n'2016'\nSex:\n'Male and Female'\nCase count:\n21117\",\"'Delaware'\n'2016'\nSex:\n'Male and Female'\nCase count:\n6001\",\"'Georgia'\n'2016'\nSex:\n'Male and Female'\nCase count:\n52056\",\"'Illinois'\n'2016'\nSex:\n'Male and Female'\nCase count:\n68954\",\"'Iowa'\n'2016'\nSex:\n'Male and Female'\nCase count:\n18146\",\"'Kansas'\n'2016'\nSex:\n'Male and Female'\nCase count:\n15312\",\"'Kentucky'\n'2016'\nSex:\n'Male and Female'\nCase count:\n27137\",\"'Louisiana'\n'2016'\nSex:\n'Male and Female'\nCase count:\n25451\",\"'Maine'\n'2016'\nSex:\n'Male and Female'\nCase count:\n8901\",\"'Mississippi'\n'2016'\nSex:\n'Male and Female'\nCase count:\n16265\",\"'Montana'\n'2016'\nSex:\n'Male and Female'\nCase count:\n6194\",\"'New Hampshire'\n'2016'\nSex:\n'Male and Female'\nCase count:\n8442\",\"'New Jersey'\n'2016'\nSex:\n'Male and Female'\nCase count:\n51521\",\"'New York'\n'2016'\nSex:\n'Male and Female'\nCase count:\n113026\",\"'North Carolina'\n'2016'\nSex:\n'Male and Female'\nCase count:\n55394\",\"'Ohio'\n'2016'\nSex:\n'Male and Female'\nCase count:\n65645\",\"'Pennsylvania'\n'2016'\nSex:\n'Male and Female'\nCase count:\n80089\",\"'West Virginia'\n'2016'\nSex:\n'Male and Female'\nCase count:\n11698\",\"'Wisconsin'\n'2016'\nSex:\n'Male and Female'\nCase count:\n32688\"],\"locations\":[\"NM\",\"AZ\",\"CA\",\"CO\",\"DC\",\"NV\",\"AK\",\"HI\",\"MA\",\"OR\",\"TX\",\"UT\",\"VA\",\"WY\",\"FL\",\"ID\",\"IN\",\"MD\",\"MI\",\"MN\",\"MO\",\"NE\",\"ND\",\"OK\",\"RI\",\"SC\",\"SD\",\"TN\",\"VT\",\"WA\",\"AL\",\"AR\",\"CT\",\"DE\",\"GA\",\"IL\",\"IA\",\"KS\",\"KY\",\"LA\",\"ME\",\"MS\",\"MT\",\"NH\",\"NJ\",\"NY\",\"NC\",\"OH\",\"PA\",\"WV\",\"WI\"],\"type\":\"choropleth\",\"marker\":{\"line\":{\"colorbar\":{\"title\":\"\",\"ticklen\":2},\"cmin\":359.4,\"cmax\":509.7,\"colorscale\":[[\"0\",\"rgba(252,251,253,1)\"],[\"0.0416666666666666\",\"rgba(248,246,250,1)\"],[\"0.0833333333333332\",\"rgba(243,242,248,1)\"],[\"0.125\",\"rgba(239,237,245,1)\"],[\"0.166666666666667\",\"rgba(232,231,242,1)\"],[\"0.208333333333333\",\"rgba(225,224,238,1)\"],[\"0.25\",\"rgba(218,218,235,1)\"],[\"0.291666666666667\",\"rgba(208,208,230,1)\"],[\"0.333333333333333\",\"rgba(198,199,225,1)\"],[\"0.375\",\"rgba(188,189,220,1)\"],[\"0.416666666666667\",\"rgba(178,177,213,1)\"],[\"0.458333333333333\",\"rgba(168,166,207,1)\"],[\"0.5\",\"rgba(158,154,200,1)\"],[\"0.541666666666667\",\"rgba(148,144,195,1)\"],[\"0.583333333333333\",\"rgba(138,135,191,1)\"],[\"0.625\",\"rgba(128,125,186,1)\"],[\"0.666666666666667\",\"rgba(121,110,178,1)\"],[\"0.708333333333333\",\"rgba(114,96,171,1)\"],[\"0.75\",\"rgba(106,81,163,1)\"],[\"0.791666666666667\",\"rgba(99,67,156,1)\"],[\"0.833333333333333\",\"rgba(92,54,150,1)\"],[\"0.875\",\"rgba(84,39,143,1)\"],[\"0.916666666666666\",\"rgba(77,28,137,1)\"],[\"0.958333333333333\",\"rgba(70,16,131,1)\"],[\"1\",\"rgba(63,0,125,1)\"]],\"showscale\":false,\"color\":[359.4,376.3,385.6,388.8,378.3,385,405.8,414.2,404.2,405.3,391.8,390.6,413.3,402.3,419.3,439.2,443,440.9,436.8,455.7,446.3,446.4,448.7,447.9,450.6,440.9,449.5,455.7,442.4,445.1,457.8,469.6,465.5,487.2,468.8,462.8,473.6,457.3,509.7,473.1,473.4,465.8,456.6,480.9,474.8,474.8,458.4,456.1,482.5,472,458.6]}},\"geo\":\"geo\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}   SessionInfo sessionInfo() ## R version 3.6.1 (2019-07-05) ## Platform: x86_64-apple-darwin15.6.0 (64-bit) ## Running under: macOS Mojave 10.14.6 ## ## Matrix products: default ## BLAS: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRblas.0.dylib ## LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRlapack.dylib ## ## locale: ## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8 ## ## attached base packages: ## [1] stats graphics grDevices utils datasets methods base ## ## other attached packages: ## [1] RCurl_1.95-4.12 bitops_1.0-6 httr_1.4.1 scales_1.1.0 ## [5] readxl_1.3.1 plotly_4.9.0 knitr_1.26 forcats_0.4.0 ## [9] stringr_1.4.0 dplyr_0.8.3 purrr_0.3.3 readr_1.3.1 ## [13] tidyr_1.0.0 tibble_2.1.3 ggplot2_3.2.1 tidyverse_1.3.0 ## ## loaded via a namespace (and not attached): ## [1] Rcpp_1.0.3 lubridate_1.7.4 lattice_0.20-38 assertthat_0.2.1 ## [5] digest_0.6.23 mime_0.7 R6_2.4.1 cellranger_1.1.0 ## [9] backports_1.1.5 reprex_0.3.0 evaluate_0.14 highr_0.8 ## [13] blogdown_0.17.1 pillar_1.4.3 rlang_0.4.4 lazyeval_0.2.2 ## [17] rstudioapi_0.10 data.table_1.12.6 rmarkdown_1.17 htmlwidgets_1.5.1 ## [21] munsell_0.5.0 shiny_1.4.0 broom_0.5.2 compiler_3.6.1 ## [25] httpuv_1.5.2 modelr_0.1.5 xfun_0.11 pkgconfig_2.0.3 ## [29] htmltools_0.4.0 tidyselect_0.2.5 bookdown_0.16 fansi_0.4.1 ## [33] viridisLite_0.3.0 crayon_1.3.4 dbplyr_1.4.2 withr_2.1.2 ## [37] later_1.0.0 grid_3.6.1 xtable_1.8-4 nlme_3.1-140 ## [41] jsonlite_1.6 gtable_0.3.0 lifecycle_0.1.0 DBI_1.0.0 ## [45] magrittr_1.5 cli_2.0.1 stringi_1.4.5 farver_2.0.3 ## [49] fs_1.3.1 promises_1.1.0 xml2_1.2.2 generics_0.0.2 ## [53] vctrs_0.2.2 RColorBrewer_1.1-2 tools_3.6.1 glue_1.3.1 ## [57] hms_0.5.2 crosstalk_1.0.0 fastmap_1.0.1 yaml_2.2.0 ## [61] colorspace_1.4-1 rvest_0.3.5 haven_2.2.0  ","date":-62135596800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":-62135596800,"objectID":"0020cd20d8d17847e698c59dd080c2fc","permalink":"/post/plotly/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/post/plotly/","section":"post","summary":"This working document is a user guide on how to create interactive graphs with R via a package called `plotly`","tags":["Plotly","Data Science"],"title":"Create Interactive Data Visualization with Plotly in R","type":"post"},{"authors":["David Michael Miller","Sophia Shalhout"],"categories":null,"content":"       Overview  This is a working document to provide a roadmap to create a FlexDashboard for Clinical Research\n Of note, the data here is completly fabricated, any relation to real subjects is completely coincidental The purpose of a FlexDashboard is to present your data in way that enhances data intrepretation or to provide patients with comprehendable information depending on how you use the data There are many excellent tutorials on using the package Flexdashboard to create a dashboard; however, we still hit many roadblocks that we hope you can avoid if you follow our instructions and code\n What we will show you next is the code we used to create the following Flesdashboard    Load Packages library(flexdashboard) library(RCurl) library(REDCapR) library(httr) library(tidyverse) library(knitr) library(plotly) library(readxl) library(scales)  Format of Flexdashboard  The Flexdashboard package is build around RMarkdown\n To start, you can open a new RMarkdown by  File -\u0026gt; New File -\u0026gt; RMarkdown Then go to “From Template” on the left hand column If you have installed Flexdashboard then Flexdashboard will be in the window that opens\n Once you have selected Flexdashboard a new RMarkdown will open What is specific here is the YAML  The content between the three dashes in beginning of the RMarkdown   This is the YAML for the Flexdashboard  title: “Untitled”\noutput:\nflexdashboard::flex_dashboard:\norientation: columns\nvertical_layout: fill\n Then after the YAML, the Flexdashboard template is quite basic\n You will generate code for the the three charts that you want displayed The template calls them Chart A, Chart B, Chart C. Each Chart is preceded by three #s and is flanked by a long series of dashes\n You can then change the title from Chart A to the title you desire\n Then following the Title, you have a “r chunk” that you use to generate your charts   Load Your Dataset  This is a fabricated dataset in Excel, but has many features that resemble an actual rare disease cohort dataset  dt \u0026lt;- read_excel(\u0026quot;mcc_cohort_fake.xlsx\u0026quot;) ## New names: ## * `` -\u0026gt; ...5  View Dataset dt %\u0026gt;% kable   record_id redcap_repeat_instrument redcap_repeat_instance redcap_data_access_group …5 age_at_dx man_clinstage man_pathstage t_stage n_stg_clin n_stg_path m_stage    1 NA NA NA NA 60 0 0 NA  2 NA NA NA NA 65 1 1 NA  3 NA NA NA NA 64 2 2 NA  4 NA NA NA NA 71 3 3 NA  5 NA NA NA NA 72 4 4 NA  6 NA NA NA NA 74 98 98 NA  7 NA NA NA NA 58 0 0 NA  8 NA NA NA NA 23 0 0 NA  9 NA NA NA NA 55 0 0 NA  10 NA NA NA NA 99 1 1 NA  11 NA NA NA NA 36 1 1 NA  12 NA NA NA NA 62 0 0 NA  13 NA NA NA NA 65 0 0 NA  14 NA NA NA NA 68 1 1 NA  15 NA NA NA NA 74 3 3 NA  16 NA NA NA NA 58 3 3 NA  17 NA NA NA NA 88 3 3 NA  18 NA NA NA NA 55 3 3 NA  19 NA NA NA NA 55 4 4 NA  20 NA NA NA NA 74 98 98 NA  21 NA NA NA NA 62 3 3 NA  22 NA NA NA NA 65 0 0 NA  23 NA NA NA NA 60 1 1 NA  24 NA NA NA NA 65 NA NA NA  25 NA NA NA NA 64 1 1 NA  26 NA NA NA NA 71 1 1 NA  27 NA NA NA NA 72 0 0 NA  28 NA NA NA NA 74 0 0 NA  29 NA NA NA NA 58 1 1 NA  30 NA NA NA NA 23 0 0 NA  31 NA NA NA NA 55 1 1 NA  32 NA NA NA NA 99 3 3 NA  33 NA NA NA NA 36 3 3 NA  34 NA NA NA NA 62 3 3 NA  35 NA NA NA NA 65 4 4 NA  36 NA NA NA NA 68 4 4 NA  37 NA NA NA NA 74 4 4 NA  38 NA NA NA NA 58 0 0 NA  39 NA NA NA NA 88 1 1 NA  40 NA NA NA NA 55 2 2 NA  41 NA NA NA NA 55 3 3 NA  42 NA NA NA NA 74 4 4 NA  43 NA NA NA NA 62 98 98 NA  44 NA NA NA NA 65 0 0 NA  45 NA NA NA NA 68 0 0 NA  46 NA NA NA NA 55 0 0 NA  47 NA NA NA NA 60 1 1 NA  48 NA NA NA NA 65 1 1 NA  49 NA NA NA NA 64 0 0 NA  50 NA NA NA NA 71 0 0 NA  51 NA NA NA NA 72 1 1 NA  52 NA NA NA NA 74 3 3 NA  53 NA NA NA NA 58 3 3 NA  54 NA NA NA NA 23 3 3 NA  55 NA NA NA NA 55 3 3 NA  56 NA NA NA NA 99 4 4 NA  57 NA NA NA NA 36 98 98 NA  58 NA NA NA NA 62 3 3 NA  59 NA NA NA NA 65 0 0 NA  60 NA NA NA NA 60 1 1 NA  61 NA NA NA NA 65 2 2 NA  62 NA NA NA NA 64 3 3 NA  63 NA NA NA NA 71 4 5 NA  64 NA NA NA NA 72 98 98 NA  65 NA NA NA NA 74 0 0 NA  66 NA NA NA NA 58 0 0 NA  67 NA NA NA NA 23 0 0 NA  68 NA NA NA NA 55 1 1 NA  69 NA NA NA NA 99 1 1 NA  70 NA NA NA NA 74 0 0 NA  71 NA NA NA NA 62 0 0 NA  72 NA NA NA NA 65 1 1 NA  73 NA NA NA NA 68 3 3 NA  74 NA NA NA NA 74 3 3 NA  75 NA NA NA NA 58 3 3 NA  76 NA NA NA NA 88 3 3 NA  77 NA NA NA NA 55 4 5 NA  78 NA NA NA NA 55 98 98 NA  79 NA NA NA NA 36 3 3 NA  80 NA NA NA NA 62 0 0 NA  81 NA NA NA NA 65 1 1 NA  82 NA NA NA NA 68 NA NA NA  83 NA NA NA NA 55 1 1 NA  84 NA NA NA NA 99 1 1 NA  85 NA NA NA NA 36 0 0 NA  86 NA NA NA NA 62 0 0 NA  87 NA NA NA NA 65 1 1 NA  88 NA NA NA NA 68 0 0 NA  89 NA NA NA NA 74 1 1 NA  90 NA NA NA NA 58 3 3 NA  91 NA NA NA NA 88 3 3 NA  92 NA NA NA NA 55 3 3 NA  93 NA NA NA NA 55 4 5 NA  94 NA NA NA NA 74 4 5 NA  95 NA NA NA NA 78 4 5 NA  96 NA NA NA NA 72 1 1 NA  97 NA NA NA NA 77 0 0 NA  98 NA NA NA NA 76 2 2 NA  99 NA NA NA NA 87 3 3 NA  100 NA NA NA NA 62 3 3 NA     Age at Diagnosis Chart Wrangle Data for Age at Diagnosis Age_at_Dx \u0026lt;- dt %\u0026gt;% select(record_id, age_at_dx) %\u0026gt;% drop_na(age_at_dx) # drop_na is a good function to eliminate rows that have missing values Age_at_Dx$subjects \u0026lt;- \u0026quot;subjects\u0026quot; # add a column that unifies all the data (helpful for plotly)   View Dataset Age at Dx Age_at_Dx %\u0026gt;% kable   record_id age_at_dx subjects    1 60 subjects  2 65 subjects  3 64 subjects  4 71 subjects  5 72 subjects  6 74 subjects  7 58 subjects  8 23 subjects  9 55 subjects  10 99 subjects  11 36 subjects  12 62 subjects  13 65 subjects  14 68 subjects  15 74 subjects  16 58 subjects  17 88 subjects  18 55 subjects  19 55 subjects  20 74 subjects  21 62 subjects  22 65 subjects  23 60 subjects  24 65 subjects  25 64 subjects  26 71 subjects  27 72 subjects  28 74 subjects  29 58 subjects  30 23 subjects  31 55 subjects  32 99 subjects  33 36 subjects  34 62 subjects  35 65 subjects  36 68 subjects  37 74 subjects  38 58 subjects  39 88 subjects  40 55 subjects  41 55 subjects  42 74 subjects  43 62 subjects  44 65 subjects  45 68 subjects  46 55 subjects  47 60 subjects  48 65 subjects  49 64 subjects  50 71 subjects  51 72 subjects  52 74 subjects  53 58 subjects  54 23 subjects  55 55 subjects  56 99 subjects  57 36 subjects  58 62 subjects  59 65 subjects  60 60 subjects  61 65 subjects  62 64 subjects  63 71 subjects  64 72 subjects  65 74 subjects  66 58 subjects  67 23 subjects  68 55 subjects  69 99 subjects  70 74 subjects  71 62 subjects  72 65 subjects  73 68 subjects  74 74 subjects  75 58 subjects  76 88 subjects  77 55 subjects  78 55 subjects  79 36 subjects  80 62 subjects  81 65 subjects  82 68 subjects  83 55 subjects  84 99 subjects  85 36 subjects  86 62 subjects  87 65 subjects  88 68 subjects  89 74 subjects  90 58 subjects  91 88 subjects  92 55 subjects  93 55 subjects  94 74 subjects  95 78 subjects  96 72 subjects  97 77 subjects  98 76 subjects  99 87 subjects  100 62 subjects     Graph your Data Plotly Graph of Age at Diagnosis plot_ly(data = Age_at_Dx, type = \u0026quot;box\u0026quot;) %\u0026gt;% add_boxplot(x = Age_at_Dx$subjects, y = Age_at_Dx$age_at_dx, boxpoints = \u0026quot;all\u0026quot;, jitter = 0.3, pointpos = -1.8, marker = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), line = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), color = I(\u0026quot;steelblue4\u0026quot;), name = \u0026quot;MGH-HCC Cohort\u0026quot;) %\u0026gt;% layout(title = \u0026quot;Age at Diagnosis of MCC\u0026quot;) ## Warning: Can\u0026#39;t display both discrete \u0026amp; non-discrete data on same axis  {\"x\":{\"visdat\":{\"75a574412421\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75a574412421\",\"attrs\":{\"75a574412421\":{\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"box\"},\"75a574412421.1\":{\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"box\",\"x\":[\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\"],\"y\":[60,65,64,71,72,74,58,23,55,99,36,62,65,68,74,58,88,55,55,74,62,65,60,65,64,71,72,74,58,23,55,99,36,62,65,68,74,58,88,55,55,74,62,65,68,55,60,65,64,71,72,74,58,23,55,99,36,62,65,60,65,64,71,72,74,58,23,55,99,74,62,65,68,74,58,88,55,55,36,62,65,68,55,99,36,62,65,68,74,58,88,55,55,74,78,72,77,76,87,62],\"boxpoints\":\"all\",\"jitter\":0.3,\"pointpos\":-1.8,\"marker\":{\"color\":\"rgb(7,40,89)\"},\"line\":{\"color\":\"rgb(7,40,89)\"},\"color\":[\"steelblue4\"],\"name\":\"MGH-HCC Cohort\",\"inherit\":true}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Age at Diagnosis of MCC\",\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":[]},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":[]},\"hovermode\":\"closest\",\"showlegend\":true},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"fillcolor\":\"rgba(31,119,180,0.5)\",\"type\":\"box\",\"marker\":{\"color\":\"rgba(31,119,180,1)\",\"line\":{\"color\":\"rgba(31,119,180,1)\"}},\"line\":{\"color\":\"rgba(31,119,180,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(54,100,139,0.5)\",\"type\":\"box\",\"x\":[\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\",\"subjects\"],\"y\":[60,65,64,71,72,74,58,23,55,99,36,62,65,68,74,58,88,55,55,74,62,65,60,65,64,71,72,74,58,23,55,99,36,62,65,68,74,58,88,55,55,74,62,65,68,55,60,65,64,71,72,74,58,23,55,99,36,62,65,60,65,64,71,72,74,58,23,55,99,74,62,65,68,74,58,88,55,55,36,62,65,68,55,99,36,62,65,68,74,58,88,55,55,74,78,72,77,76,87,62],\"boxpoints\":\"all\",\"jitter\":0.3,\"pointpos\":-1.8,\"marker\":{\"color\":\"rgb(7,40,89)\",\"line\":{\"color\":\"rgba(54,100,139,1)\"}},\"line\":{\"color\":\"rgb(7,40,89)\"},\"name\":\"MGH-HCC Cohort\",\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}   Bar Chart of Stage of Diagnosis cStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_clinstage) %\u0026gt;% filter(man_clinstage \u0026lt; 98) cStageDF \u0026lt;- cStage %\u0026gt;% group_by(man_clinstage) %\u0026gt;% tally() plot_ly(data = cStageDF) %\u0026gt;% add_bars(x = cStageDF$man_clinstage, y = cStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Clinical Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Clincal Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;III\u0026quot;, \u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4)))  {\"x\":{\"visdat\":{\"75a56633406\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75a56633406\",\"attrs\":{\"75a56633406\":{\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"x\":[0,1,2,3,4],\"y\":[27,23,4,26,12],\"type\":\"bar\",\"color\":[\"steelblue4\"],\"inherit\":true}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Clinical Stage at Presentation\",\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Number of Subjects\"},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Clincal Stage\",\"ticktext\":[\"I\",\"IIA\",\"IIB\",\"III\",\"IV\"],\"tickvals\":[0,1,2,3,4]},\"hovermode\":\"closest\",\"showlegend\":false},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[0,1,2,3,4],\"y\":[27,23,4,26,12],\"type\":\"bar\",\"marker\":{\"color\":\"rgba(54,100,139,1)\",\"line\":{\"color\":\"rgba(54,100,139,1)\"}},\"textfont\":{\"color\":\"rgba(54,100,139,1)\"},\"error_y\":{\"color\":\"rgba(54,100,139,1)\"},\"error_x\":{\"color\":\"rgba(54,100,139,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}  BarChart of Pathological Staging at Diagnosis pStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_pathstage) %\u0026gt;% filter(man_pathstage \u0026lt; 6) pStageDF \u0026lt;- pStage %\u0026gt;% group_by(man_pathstage) %\u0026gt;% tally() plot_ly(data = pStageDF) %\u0026gt;% add_bars(x = pStageDF$man_pathstage, y = pStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Pathological Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Pathological Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;IIIA\u0026quot;, \u0026quot;IIIB\u0026quot;,\u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4, 5)))  {\"x\":{\"visdat\":{\"75a55b086cf2\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"75a55b086cf2\",\"attrs\":{\"75a55b086cf2\":{\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"x\":[0,1,2,3,4,5],\"y\":[27,23,4,26,7,5],\"type\":\"bar\",\"color\":[\"steelblue4\"],\"inherit\":true}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Pathological Stage at Presentation\",\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Number of Subjects\"},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Pathological Stage\",\"ticktext\":[\"I\",\"IIA\",\"IIB\",\"IIIA\",\"IIIB\",\"IV\"],\"tickvals\":[0,1,2,3,4,5]},\"hovermode\":\"closest\",\"showlegend\":false},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[0,1,2,3,4,5],\"y\":[27,23,4,26,7,5],\"type\":\"bar\",\"marker\":{\"color\":\"rgba(54,100,139,1)\",\"line\":{\"color\":\"rgba(54,100,139,1)\"}},\"textfont\":{\"color\":\"rgba(54,100,139,1)\"},\"error_y\":{\"color\":\"rgba(54,100,139,1)\"},\"error_x\":{\"color\":\"rgba(54,100,139,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]} Recapitulate the RMarkdown with the Flexdashboard Template  What we have above is a step by step of what the data looks like to generate the Flexddashboard and essentially all of the code used to generate the figures\n What we have below is a more direct representation of where you would put that code to generate the following Flexdashboard  You will see essentially 3 r chunks and all of the code used placed into those three; including the code to load the data, that can go in the first code chunk under the ### Chart A section   Column {data-width=650} Chart A - Age at Diagnosis dt \u0026lt;- read_excel(\u0026quot;mcc_cohort_fake.xlsx\u0026quot;) # Load the data Age_at_Dx \u0026lt;- dt %\u0026gt;% select(record_id, age_at_dx) %\u0026gt;% drop_na(age_at_dx) # drop_na is a good function to eliminate rows that have missing values Age_at_Dx$subjects \u0026lt;- \u0026quot;subjects\u0026quot; # add a column that unifies all the data (helpful for plotly) Age_at_Dx %\u0026gt;% kable plot_ly(data = Age_at_Dx, type = \u0026quot;box\u0026quot;) %\u0026gt;% add_boxplot(x = Age_at_Dx$subjects, y = Age_at_Dx$age_at_dx, boxpoints = \u0026quot;all\u0026quot;, jitter = 0.3, pointpos = -1.8, marker = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), line = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), color = I(\u0026quot;steelblue4\u0026quot;), name = \u0026quot;MGH-HCC Cohort\u0026quot;) %\u0026gt;% layout(title = \u0026quot;Age at Diagnosis of MCC\u0026quot;)   Column {data-width=350} Chart B - Clinical Stage at Diagnosis cStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_clinstage) %\u0026gt;% filter(man_clinstage \u0026lt; 98) cStageDF \u0026lt;- cStage %\u0026gt;% group_by(man_clinstage) %\u0026gt;% tally() plot_ly(data = cStageDF) %\u0026gt;% add_bars(x = cStageDF$man_clinstage, y = cStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Clinical Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Clincal Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;III\u0026quot;, \u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4)))  Chart C - Pathological Stage at Diagnosis pStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_pathstage) %\u0026gt;% filter(man_pathstage \u0026lt; 6) pStageDF \u0026lt;- pStage %\u0026gt;% group_by(man_pathstage) %\u0026gt;% tally() plot_ly(data = pStageDF) %\u0026gt;% add_bars(x = pStageDF$man_pathstage, y = pStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Pathological Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Pathological Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;IIIA\u0026quot;, \u0026quot;IIIB\u0026quot;,\u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4, 5))) This is what that RMarkdown looks like with the FlexDashbaord Template  If you have many charts that you would like to include on your dashboard, you may want to divide the dashboard into multiple pages. Each page is defined by a level 1 markdown header, (=========), and will have an individual navigation tab.  For example, in the data shown above, we may want to have age of diagnosis of MCC on a page by itself, and the clinical and pathological staging on a second page in the dashboard.     PAGE 1: Age at Diagnosis of MCC Chart A - Age at Diagnosis of MCC dt \u0026lt;- read_excel(\u0026quot;mcc_cohort_fake.xlsx\u0026quot;) # Load the data Age_at_Dx \u0026lt;- dt %\u0026gt;% select(record_id, age_at_dx) %\u0026gt;% drop_na(age_at_dx) # drop_na is a good function to eliminate rows that have missing values Age_at_Dx$subjects \u0026lt;- \u0026quot;subjects\u0026quot; # add a column that unifies all the data (helpful for plotly) Age_at_Dx %\u0026gt;% kable plot_ly(data = Age_at_Dx, type = \u0026quot;box\u0026quot;) %\u0026gt;% add_boxplot(x = Age_at_Dx$subjects, y = Age_at_Dx$age_at_dx, boxpoints = \u0026quot;all\u0026quot;, jitter = 0.3, pointpos = -1.8, marker = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), line = list(color = \u0026#39;rgb(7,40,89)\u0026#39;), color = I(\u0026quot;steelblue4\u0026quot;), name = \u0026quot;MGH-HCC Cohort\u0026quot;) %\u0026gt;% layout(title = \u0026quot;Age at Diagnosis of MCC\u0026quot;)   PAGE 2: Staging of MCC Column {data-width=350}` Chart B - Clinical Stage at Diagnosis of MCC cStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_clinstage) %\u0026gt;% filter(man_clinstage \u0026lt; 98) cStageDF \u0026lt;- cStage %\u0026gt;% group_by(man_clinstage) %\u0026gt;% tally() plot_ly(data = cStageDF) %\u0026gt;% add_bars(x = cStageDF$man_clinstage, y = cStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Clinical Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Clincal Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;III\u0026quot;, \u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4)))  Chart C - Pathological Stage at Diagnosis of MCC pStage \u0026lt;-dt %\u0026gt;% select(record_id, man_clinstage, man_pathstage) %\u0026gt;% drop_na(man_pathstage) %\u0026gt;% filter(man_pathstage \u0026lt; 6) pStageDF \u0026lt;- pStage %\u0026gt;% group_by(man_pathstage) %\u0026gt;% tally() plot_ly(data = pStageDF) %\u0026gt;% add_bars(x = pStageDF$man_pathstage, y = pStageDF$n, color = I(\u0026quot;steelblue4\u0026quot;)) %\u0026gt;% layout( title = \u0026quot;Pathological Stage at Presentation\u0026quot;, yaxis = list(title = \u0026quot;Number of Subjects\u0026quot;), xaxis = list(title = \u0026quot;Pathological Stage\u0026quot;, ticktext = list(\u0026quot;I\u0026quot;, \u0026quot;IIA\u0026quot;, \u0026quot;IIB\u0026quot;, \u0026quot;IIIA\u0026quot;, \u0026quot;IIIB\u0026quot;,\u0026quot;IV\u0026quot;), tickvals = list(0, 1, 2, 3, 4, 5))) This is what page 1 of the dashboard now looks like. And this is what page 2 of the dashboard now looks like. # Session Info\nsessionInfo() ## R version 3.6.1 (2019-07-05) ## Platform: x86_64-apple-darwin15.6.0 (64-bit) ## Running under: macOS Mojave 10.14.6 ## ## Matrix products: default ## BLAS: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRblas.0.dylib ## LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRlapack.dylib ## ## locale: ## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8 ## ## attached base packages: ## [1] stats graphics grDevices utils datasets methods base ## ## other attached packages: ## [1] scales_1.1.0 readxl_1.3.1 plotly_4.9.0 ## [4] knitr_1.26 forcats_0.4.0 stringr_1.4.0 ## [7] dplyr_0.8.3 purrr_0.3.3 readr_1.3.1 ## [10] tidyr_1.0.0 tibble_2.1.3 ggplot2_3.2.1 ## [13] tidyverse_1.3.0 httr_1.4.1 REDCapR_0.10.2 ## [16] RCurl_1.95-4.12 bitops_1.0-6 flexdashboard_0.5.1.1 ## ## loaded via a namespace (and not attached): ## [1] Rcpp_1.0.3 lubridate_1.7.4 lattice_0.20-38 assertthat_0.2.1 ## [5] digest_0.6.23 mime_0.7 R6_2.4.1 cellranger_1.1.0 ## [9] backports_1.1.5 reprex_0.3.0 evaluate_0.14 highr_0.8 ## [13] blogdown_0.17.1 pillar_1.4.3 rlang_0.4.4 lazyeval_0.2.2 ## [17] rstudioapi_0.10 data.table_1.12.6 rmarkdown_1.17 htmlwidgets_1.5.1 ## [21] munsell_0.5.0 shiny_1.4.0 broom_0.5.2 httpuv_1.5.2 ## [25] compiler_3.6.1 modelr_0.1.5 xfun_0.11 pkgconfig_2.0.3 ## [29] htmltools_0.4.0 tidyselect_0.2.5 bookdown_0.16 fansi_0.4.1 ## [33] viridisLite_0.3.0 later_1.0.0 crayon_1.3.4 dbplyr_1.4.2 ## [37] withr_2.1.2 grid_3.6.1 xtable_1.8-4 nlme_3.1-140 ## [41] jsonlite_1.6 gtable_0.3.0 lifecycle_0.1.0 DBI_1.0.0 ## [45] magrittr_1.5 cli_2.0.1 stringi_1.4.5 promises_1.1.0 ## [49] fs_1.3.1 xml2_1.2.2 ellipsis_0.3.0 generics_0.0.2 ## [53] vctrs_0.2.2 tools_3.6.1 glue_1.3.1 hms_0.5.2 ## [57] crosstalk_1.0.0 fastmap_1.0.1 yaml_2.2.0 colorspace_1.4-1 ## [61] rvest_0.3.5 haven_2.2.0    ","date":-62135596800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":-62135596800,"objectID":"1f8e1a11183646a99e024a77ef9d0c46","permalink":"/post/flexdashboards/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/post/flexdashboards/","section":"post","summary":"This working document is a user guide on how to create a Flexdashboards using R via a package called `flexdashboard`","tags":["FlexDashboard","Data Science"],"title":"FlexDashboards for Clinical and Translational Research","type":"post"}]